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Abstract
Alcohol use disorder is a chronic condition characterized by an inability to
control alcohol intake. Recent research has shown that appetite-regulating
hormones, ghrelin, and leptin, may play a role in alcohol craving. In addition, it is
known that food and alcohol craving have overlapping receptors in the brain
reward system. Ghrelin, a naturally occurring hormone in the human body, is
produced mainly by ghrelinergic cells of the gastric mucosa. Once the hormone
crosses the blood-brain barrier, it binds to growth hormone secretagogue
receptor (ghrelin receptor) in the hypothalamus and stimulates the appetite and
food intake. Leptin, a hormone produced from adipose tissue has an opposite
effect to that of ghrelin and reduces hunger. Leptin and ghrelin work in tandem to
maintain energy homeostasis in the body. It was demonstrated that antagonizing
ghrelin

receptor

reduces

alcohol

craving

thus

making

it

a

potential

pharmacological target to treat alcohol use disorders.
PF-5190457 is a highly selective, orally bioavailable ghrelin receptor
inverse agonist developed by Pfizer. PF-5190457 was made available for
research by the National Center for Advancing Translational Sciences (NCATS)
under the NIH New Therapeutic Uses Pilot Program. Initial studies by Pfizer had
shown that the compound is safe and well tolerated in healthy volunteers after
oral administration. To date, the compound has completed Phase 1b clinical trials
in nontreatment-seeking patients with alcohol use disorder. The plasma samples
obtained from the study was evaluated for the pharmacokinetics of PF-5190457
and its major hydroxy metabolite. In order to measure the concentration of the

drug and its metabolite, a liquid chromatography tandem mass spectroscopy
method (LC-MS/MS) was developed and validated as described in Manuscript I
(to be submitted to Journal of Chromatography B: Biomedical Sciences and
Applications). The manuscript describes a new LC-MS/MS method developed for
this purpose and the assay was fully validated according to the FDA guidance
document for bioanalytical methods. The analytes of interest were extracted from
plasma with methanol using a simple protein precipitation technique, and tacrine
was used as the internal standard. All the bioanalysis method parameters, i.e.,
sensitivity, specificity, linearity, accuracy, precision, matrix effect, recovery, and
stability were within the recommended FDA guidelines. Incurred sample
reanalysis (10% of the patient plasma samples) was performed to evaluate the
repeatability of the new method and was found to be within the acceptance
criteria.
Manuscript II (to be submitted to Drug Metabolism and Disposition)
describes the biotransformation of PF-5190457 (molecular weight: 513). Before
this work in our lab, no information on the metabolism of the PF-5190457 in
humans was available. Extensive LC-MS/MS profiling of plasma from Phase 1b
study showed many circulating metabolites. Subsequent analysis revealed the
presence of a significant hydroxy metabolite (m/z 529) along with minor
glucuronide and hydroxy glucuronide metabolites. Further exploration of the
fragmentation pattern of the major hydroxy metabolite (m/z 351 and m/z 225)
suggested possible hydroxylation between the two nitrogen atoms of the drug. In
parallel, in vitro experiments were conducted in human hepatic microsomes and

cytosolic fractions to characterize the drug metabolism enzymes responsible for
the formation of metabolites. Preliminary data revealed the formation of hydroxy
metabolite in the cytosol but not in the microsomes. The reaction was found to be
independent of the presence of nicotinamide adenine dinucleotide phosphate
(NADPH) in the incubation media. Addition of a non-selective CYP450 inhibitor
(1-amino benzotriazole) inhibited the formation of all the minor metabolites but
not the hydroxy metabolite. A comparative mass spectra analysis showed the
presence of hydroxy metabolite in the human liver cytosol incubations which was
previously found in human plasma. PF-5190457 was also incubated in
hepatocytes leading to the formation of major and minor metabolites. Further
addition of an aldehyde oxidase inhibitor (hydralazine) in hepatocytes completely
inhibited the formation of the hydroxy metabolite indicating the involvement of
aldehyde oxidase in the metabolism of the PF-5190457. The hydroxy metabolite
was also found in incubations conducted with PF-5190457 and cytosol from
different animal species. The aldehyde oxidase metabolite of PF-5190457 was
biosynthesized, from female mouse liver cytosol and the structure of the
metabolite was confirmed using NMR analysis indicating the hydroxylation
position to be on the pyrimidine ring between the two nitrogen atoms. Literature
shows both aldehyde and xanthine oxidase share substrate specificity. Specific
inhibitors of both the enzymes were used to identify their involvement in the
metabolism of the drug. Raloxifene and febuxostat were used as selective
aldehyde oxidase and xanthine oxidase inhibitor, in human liver cytosol
incubations with PF-5190457 respectively. The data from inhibition study

suggested a role for both the enzymes in the biotransformation of the drug with
aldehyde oxidase enzyme being dominant over xanthine oxidase. The kinetic
parameters Km and Vmax for hydroxy metabolite formation in human liver
cytosol were 42 ± 4 µM and 0.12 ± 0.003 nmol/min/mg protein, respectively.
Aldehyde oxidase (AOX1) is gaining increased attention for its role in the
metabolism of new drug candidates. A significant variability in the levels of the
AOX1 protein expression in the human liver has been reported in published
studies. We assessed the AOX1 levels in a novel repository of human liver
(n=104) using mass spectroscopy as described in Manuscript III (to be
submitted to Drug Metabolism and Disposition). The levels of AOX1 were
estimated using traditional data-dependent acquisition and upcoming SWATHMS method. A strong and significant correlation (Spearman r-0.72, P<0.0001)
was observed between the two methods making a case for the use of SWATH
based methods in the field of drug metabolism. Expression levels of AOX1
determined in our liver bank using MaxQuant (proteomics data analysis software)
were found to be well within the literature reported range (2 - 49 pmol/mg total
cytosolic protein). Further, we evaluated the effect of demographic factors
(gender, age, ethnicity, drug usage, alcohol consumption, and smoking) and
disease conditions (diabetes, non-alcoholic fatty liver disease) on the AOX1
expression. We found no significant association between demographic factors
with the expression of the AOX1 protein. Similarly, disease conditions were not
found to influence the expression of AOX1 indicating other unidentified factors
influencing the enzyme expression.

Manuscript

IV

(to

be

submitted

to

British

Journal

of

Clinical

Pharmacology) outlines the pharmacokinetics data via non-compartmental
analysis of PF-5190457 and its hydroxy metabolite. The concentrations of
analytes from phase 1b trials were evaluated in N=12 patients at placebo, 50 and
100 mg doses using validated LC-MS/MS method as described in Manuscript I.
The half-life of the metabolite (~13 h) was found to be longer than the parent
drug (~6 h). Additionally, the rate of formation of hydroxy metabolite was studied
in cytosol prepared from 10 human liver samples. The rate of formation of
hydroxy metabolite was found to be highly variable with a 20.5-fold (0.02 – 0.41
nmol/min/mg protein) variation among the ten samples. Interestingly, the AOX1
protein expression for same samples showed only 2.5-fold variability (16.8 - 44.1
pmol/mg protein).
In summary, an understanding of the enzymes responsible for the
metabolism of a drug is essential to avoid drug-drug interactions or the presence
of polymorphic enzymes interfering with the therapeutic outcome of the drug.
Collectively, we for the first time determined the clinical pharmacokinetics of PF5190457 and its major metabolite (hydroxy metabolite) in alcoholic patients.
Further studies suggested the involvement of aldehyde oxidase (major role) and
xanthine oxidase (minor role) in the metabolism of the PF-5190457. Moreover, to
examine the variability in the protein expression of the enzymes, we quantified
AOX1 in a large liver databank. This work also makes a case for considering
non-cytochrome-P450 enzymes in the early screening during drug discovery.
Considering the longer half-life of metabolite than the parent, it will be warranted

to investigate the pharmacological properties of hydroxy metabolite in future
studies.
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Abstract
PF-5190457 is a selective and potent ghrelin receptor inverse agonist
presently undergoing clinical trials to treat alcoholism. We have established a
selective and sensitive liquid chromatography-tandem mass spectrometry
method for determination of PF-5190457 and its hydroxy metabolite (PF6870961) in human plasma and validated the assay according to FDA guidelines.
Plasma samples were prepared by simple protein precipitation in methanol using
tacrine as an internal standard (IS). Chromatographic separation was carried out
on an Acquity UPLC BEH C18 (2.1mm×50mm) column with 1.7 μm particle size
and 130 Å pore size column at a flow rate of 0.25 mL/min by a gradient method
with a runtime of 11.30 min. Detection was performed using multiple reaction
monitoring (MRM) at positive ion mode with two fragments for each analyte.
Tacrine was found to be a suitable IS. The calibration curves were linear in the
concentration range of 1-1000 ng/mL and 2-250 ng/mL for PF-5190457 and
hydroxy metabolite respectively with a correlation coefficient ≥0.996. The interassay precision and accuracy results obtained were within the

FDA

recommended guidelines. The analytes were found to be stable under varied
stability conditions. The validated method was utilized to measure plasma
concentration of PF-5190457 and its hydroxy metabolite in clinical studies.
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Abbreviations
CV Coefficient of variation
IS Internal standard
LLOQ Lower limit of quantification
ME Matrix effect
MeOH Methanol
MRM Multiple reaction monitoring
MS Mass spectrometry
Mw Molecular weight
PLs Phospholipids
QCs Quality controls
UPLC-MS/MS
spectrometry

Ultra-performance

liquid
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chromatography-tandem

mass

1.

Introduction
PF-5190457 (Fig. 1) is a novel peripherally acting inverse agonist of

ghrelin receptor discovered by Pfizer pharmaceuticals. It is a small molecule with
a molecular weight (Mw) 512.67 belonging to a member of spiro-azetidinopiperidine series [1, 2]. Ghrelin, an endogenous peptide released from the
stomach, is a ligand for growth hormone secretagogue receptor in the
hypothalamus and regulates appetite and food intake in the body [3-5].
Antagonists of ghrelin could be potentially therapeutic to treat type 2 diabetes
mellitus, eating disorders, obesity, and alcohol use disorder. They are believed to
regulate these disorders by stimulating glucose-dependent insulin secretion,
reduce food intake and craving for alcohol consumption respectively [6-12].
Clinical studies of PF-5190457 in healthy volunteers showed the drug is
well-tolerated and exhibit linear pharmacokinetics [13].

Following oral

administration, PF-5190457 is rapidly absorbed with a Tmax of 0.3-3 hour and its
elimination half-life (t1/2 ) was ~8 h [13]. The metabolism pathway of PF-5190457
suggests cytosolic oxidative reaction involving molybdenum co-factor containing
enzymes, aldehyde oxidase, and xanthine oxidase, leading to the formation of a
hydroxy metabolite (Figure 1b) (Manuscript II). PF-5190457 is currently
undergoing clinical trials for the treatment for alcohol use disorder and type 2
diabetes [8, 14].
Previously developed validated UPLC-MS/MS method in the laboratory
did not include the hydroxy metabolite in the assay [14]. The current manuscript
5

demonstrates a simple and selective ultra performance liquid chromatographytandem mass spectroscopy (UPLC-MS/MS) for simultaneous determination of
PF-5190457 and its hydroxy metabolite (PF-6870961) in human plasma using
tacrine as an IS. The present method is established with the aim of determining
PF-5190457 and its hydroxy metabolite in plasma samples obtained in clinical
trials of patients with alcohol use disorder.

6

2.

Materials and methods

2.1. Chemicals and reagents

PF-5190457 and tacrine (Mw 198.26) were obtained from Sigma-Aldrich
(St. Louis, MO, USA). PF-6870961 (hydroxy metabolite, Mw 528.23) was
synthesized as described in the Manuscript II.

LC-MS grade methanol and

formic acid were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Blank
K2EDTA human plasma from six subjects (three male, three female) was
obtained from Bioreclamation (IVT Inc., Westbury, NY, USA).

2.2. LC–MS/MS instrumentation, conditions and data processing

The liquid chromatography separation was performed using an Acquity
UPLC system comprising with a binary pump and a built-in column heater. A 10
μL sample loop was used to inject samples in partial loop injection mode.
Chromatography separation of analytes and IS was accomplished within 11.30
min using gradient elution method using an Acquity UPLC BEH C18 (2.1 x 50
mm, 1.7 µm particle size, 130Ǻ pore size) analytical column. An Acquity UPLC
BEH C18 VanGuard pre-column (2.1 x 5 mm, 130Ǻ) was used prior to the
analytical column. Mobile phase consisted of water: methanol 95:5% (v/v)
containing 0.1% formic acid (A) and 100% methanol containing 0.1% formic acid
(B). The column and autosampler temperature were kept at 40 °C and 10 °C,
7

respectively. The mobile phase was delivered at 0.25 mL/min flow rate, and the
injection volume was 5 µL. The initial conditions of mobile phase (98% A, 2% B)
was maintained for 2 min, B was increased from 2% to 80% over 8.30 min, and
held till 9.30 min and returned to initial conditions, followed by a 2 min
equilibration for a total run time of 11.30 min.
Mass spectral analysis and quantification was carried out using multiple
reaction monitoring (MRM) on a positive electrospray ionization mode with the
following parameters: desolvation temperature of 350°C, desolvation gas flow
650 L/h, capillary voltage 3.50 kV and cone voltage 20 V. The fragmentation
pattern for PF-5190457 and IS were similar to previously reported methods [1416]. The optimized settings of mass spectrometer voltage and the retention time
for analytes and internal standards with quantifier and qualifier fragments are
summarized in Table 1.
Data acquisition and processing were performed using MassLynx™
software (V 4.1) and TargetLynx™ tool respectively. Calibration curves were
constructed by calculating the analyte to IS peak area ratio against analyte
concentrations.

2.3. Preparation of calibration standards, quality controls, and internal standard

Sub stock solutions of PF-5190457 and hydroxy metabolite were separately
prepared in 50% methanol to obtain a final concentration of 10 µg/mL and were
stored at 4°C. Working stock solutions for calibration and quality controls were
8

prepared from the stock solution by adequate dilution using diluent (methanol:
water, 50:50, v/v). The calibration standards and quality control samples were
prepared by spiking appropriate amount of the standard working solutions into
pooled K2EDTA human plasma with an organic solvent concentration less than
5% of the final volume. An eight-point calibration curve with concentrations
ranging from 1-1000 ng/mL and 2-250 ng/mL for PF-5190457 and hydroxy
metabolite were prepared respectively. Low, medium and high level QC samples
were prepared for PF-5190457 (3, 200 and 750 ng/mL) and hydroxy metabolite
(5, 25 and 200 ng/mL), respectively. A final working solution of 2.5 ng/mL tacrine
(IS) in methanol was prepared.

2.4. Sample extraction procedure

Samples were prepared by a simple and direct protein precipitation. To
0.050 mL of sample was added 0.200 mL of precipitating solution containing IS in
methanol. IS in methanol was added to all samples except blank. Control blank
was extracted with IS whereas, the double blank was extracted in 100%
methanol without any IS. The mixture was vortex mixed for 15 seconds, and then
centrifuged at 10,000 rpm for 5 min. The clear supernatant (0.150 mL) was
collected for further analysis.

2.5. Method validation
9

The validation of this assay was performed according to the requirements
as outlined in guidelines established by the US Food and Drug Administration
(US FDA) to evaluate the method with respect to selectivity, sensitivity, linearity,
accuracy, precision, recovery, matrix effect, recovery and stability of analytes
[17].
2.5.1. Specificity and Sensitivity
The method specificity was evaluated prior to the main validation batches
for the presence of interference from endogenous compounds by screening
blank plasma of six donors. The sensitivity of the assay was evaluated by
analyzing blank plasma samples from six different donors and spiked plasma
samples at the lower limit of quantification (LLOQ) levels of the analytes.
2.5.2. Linearity, accuracy, and precision
The linearity of the method was determined by analysis of standard plots
associated with an eight-point calibration curve. Inter-assay precision and
accuracy were calculated after the replicates in six different analytical runs. Peak
area ratios of analytes to IS obtained from MRM were utilized for the construction
of calibration curves, using least squares weighted (1/x) linear regression. Carry
over test was assessed to demonstrate any carryover effect of analytes and IS.
2.5.3. Matrix effect and Recovery

10

The components present in the matrix (plasma) can interfere with
ionization efficiency by coeluting with analytes of interest [18]. Matrix effect for
ion suppression and enhancement was assessed using blank and spiked human
plasma using post column infusion experiment as described previously [14, 19].
The chromatograms can be visually evaluated to verify there are no interfering
peaks at the elution time of analytes and IS. Likewise, the interference of
phospholipids was determined as they are highly abundant endogenous
compounds in biological membranes and can interfere with elution of analytes
[20, 21]. The major transitions of phospholipids were monitored with the
precursor ion (Q1) at m/z 496, 522, 524, 758 and 782 and product ion (Q3) with
m/z 184 in the method [22]. Recovery was determined at two concentration
levels (LQC and HQC) by comparing the peak area of the analytes from the preextracted plasma standard with that obtained from post-extracted standard at the
same concentration for the QC samples.
2.5.4. Stability
Stability of analytes were evaluated at two concentrations (LQC and
HQC). The freeze–thaw stability was evaluated after undergoing three freeze
thaw cycles, benchtop stability for 6 h and short-term stability was assessed after
storage of the test samples at −80°C for 1 week. The autosampler storage
stability was determined by storing the QC samples for ~48 h under autosampler
condition (maintained at 10 C) before being analyzed.

11

2.5.5. Sample Reanalysis
The

results from

previously

validated

UPLC-MS/MS

method

for

determination of PF-5190457 in patient plasma samples (n=45) by the laboratory
was correlated with the current method to test the assay’s ability to reproduce the
data [14]. Plasma samples were obtained after oral administration of PF-5190457
from phase 1b clinical study (NCT02039349) in alcoholic patients conducted at
the clinical research center (NIH clinical center at Bethesda, MD, USA). Incurred
sample reanalysis (ISA) was performed to corroborate the results utilizing clinical
samples. Samples (10% of the study size) around Cmax and terminal elimination
phase were selected, reanalyzed and compared to the initial results obtained
from clinical samples (described below). The results of repeated analysis were
compared with original data, according to the following formula: (repeated
sample − original sample) × 100/mean value. Two-thirds of the samples
reanalyzed should be within ±20% between the two analyses [23].

12

3.

Results and Discussion

3.1. LC-MS assay
The goal of this work was to develop and validate a simple and sensitive
assay method for the simultaneous determination of PF-5190457 and its hydroxy
metabolite in human plasma. The MS optimization was performed by direct
infusion of solutions of PF-5190547, hydroxy metabolite and IS into the ESI
source of the mass spectrometer. The best signal for both the analytes and IS
was achieved using a positive ion mode. Protonated adducts for PF-5190547
(m/z 513) and hydroxy metabolite (m/z 529) and their respective high intensity
fragments (m/z 209 and m/z 225) were selected respectively for quantification.
Several trials for chromatographic conditions were performed especially to
select an optimal mobile phase and analytical C18 columns. These trials
determined

that

the present method

achieved

an optimal degree

of

chromatographical separation for simultaneous separation of different hydroxy
metabolites as well as the parent drug.

3.2. Sample preparation optimization:

A simple protein precipitation technique was utilized for the extraction of
analytes and IS from the plasma samples. Acetonitrile, methanol, DMSO, 50%
DMSO, 50% acetonitrile, 50% methanol mixture were investigated as organic
solvents for stock solution preparation. It was noticed that the metabolite was
13

unstable in acetonitrile. Methanol was then chosen as the organic solvent for
preparation of stock solution for the analytes and IS as well as only methanol
was used in mobile phase.

3.3. Selection of internal standard

The stable isotopically labeled IS was not available for hydroxy metabolite
and therefore we have demonstrated the suitability of readily available, costeffective compounds with no evidence of cross-talk with the analytes of interest
in the current assay. Various compounds with similar LogP and Pka to that of
analytes like indoprofen, chloroxazane, naproxen, tacrine and rifampicin were
tested for selection of suitable IS for the assay. Tacrine was deemed to be the
most suitable IS for quantification of PF-5190457 and hydroxy metabolite as it
ionizes in the same polarity along with the respective analytes.

3.4. Method Validation

3.4.1. Specificity and selectivity
The determination of PF-5190547, hydroxy metabolite and IS at their
respective retention time were not affected by interference from co-extracted
matrix components under the present LC–MS/MS conditions used in blank
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plasma obtained from six different donors. Sensitivity was determined by
comparing the baseline from blank plasma obtained from six different donors in
comparison to that spiked with analytes at LLOQ. There was no interference
observed from endogenous compounds. The representative extracted ion
chromatograms of the analytes and the IS in human plasma are shown in Figure
2.

3.4.2. Linearity, Precision and Accuracy
Calibration was found to be linear over the concentration range of 1-1000
ng/mL for PF-5190547 and 2-250 ng/mL for hydroxy metabolite. The curve was
fitted with linear regression using 1/x weighing function. The percentage
deviation for PF-5190547 and hydroxy metabolite was less than 8.2% and 12.2%
respectively (Table 2). The accuracy ranged from 96.2% to 113.2% for PF5190547 and 88.0% to 106.6% for hydroxy metabolite. The correlation
coefficients (r2) for PF-5190547 and hydroxy metabolite were greater than 0.997
and 0.996 respectively for all curves. Precision and accuracy for this method was
controlled by calculating the inter-batch variations of LLOQ and QC samples at
four concentrations for PF-5190547 (1, 3, 200 and 750 ng/mL) and hydroxy
metabolite (2, 5, 25 and 200 ng/mL) as shown in Table 3. The inter-day precision
of 2.4–7.4% for PF-5190547 and 3.6–6% for hydroxy metabolite. This method
demonstrated inter-day accuracy 88–104.2% for PF-5190547 and 97.2–109.7%
for the hydroxy metabolite. There was no between-sample carryover detected
following the double blank injections.
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3.4.3. Matrix effect and Recovery
In the present study, the determination of PF-5190547 and hydroxy
metabolite is not affected by co-extracted matrix components under the LC–
MS/MS conditions used Figure 3a. There was no interference from the
phospholipids on the elution of analytes Figure 3b. The percent mean recovery
for PF-5190547 and hydroxy metabolite ranged from 95-103%.

3.4.4. Stability
The data representing the stability in plasma at two concentration levels
(LQC and HQC) for PF-5190547 and hydroxy metabolite for bench top stability,
three freeze and thaw cycles, autosampler and short-term stability are given in
Table 4. These results indicate that the analytes are stable in human plasma as
the mean of the results of the tested samples were within the acceptance criteria
of ± 15% of the nominal concentrations. These findings suggest no stabilityrelated problems would be expected during pharmacokinetic studies and
analysis.

3.4.5. Sample Reanalysis
The patient samples (n=45) previously analyzed by UPLC-MS/MS method
and subsequently analyzed by the current method were within ± 15.2% for PF5190457. The data generated by this method is reproducible despite differing the
LC-MS/MS conditions. Method reproducibility was also determined by ISA (n=45)
16

following the FDA Guidance for Industry for parent and metabolite. More than
two-thirds of the sample were within ± 20%. The incurred sample analysis
indicates that both parent and its metabolite are stable within human plasma from
subjects. Bland- Altman plot is recommended over Pearson’s or Spearman’s
correlation coefficient for correlation analysis for ISA as the range of data can
influence the correlation [23]. The correlation between both the LC-MS/MS
methods and ISA for PF-5190457 and hydroxy metabolite are depicted via
Bland–Altman plots in Figure 4(a)-(c).

3.5. Method Application
The present validated method has been successfully applied to measure
the concentration of PF-5190547 and its hydroxy metabolite after oral
administration (50 mg and 100 mg) in human plasma obtained from phase 1b
pharmacokinetics alcoholic patients admited to the clinical research center (NIH
clinical center at Bethesda) for three visits (placebo, a dose of 50 mg and a dose
of 100 mg). The study was approved by the University of Rhode Island
Institutional Review Board HU# 123.172. The participants have filled out the
informed consent form prior to the study. The plasma concentration ranges of
PF-5190547 and hydroxy metabolite were measurable within their calibration
curves. Figure 5 represents plasma concentration time profile after an oral dose
of 50 mg dose in a study subject.
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4.

Conclusion

In this manuscript, we describe development of a sensitive LC–MS/MS for
the accurate, precise and reliable measurement of PF-5190547 and its hydroxy
metabolite in human plasma. This study demonstrates the suitability of tacrine as
IS for accurate quantification of PF-5190547 and hydroxy metabolite. This
method demonstrated adequate reliability and reproducibility of the results within
the analytical range. We have shown that PF-5190547 and hydroxy metabolite
are stable in human plasma under different storage conditions. This assay was
successfully employed for determination concentration of PF-5190457 and the
metabolite in a phase 1b clinical trial.
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Tables Legend
Table 1. Mass spectrometry parameters for analytes and IS
Table 2. Summary of calibration standards from six validation runs
Table 3. Summary of QC samples from six validation runs
Table 4. Summary of stability studies

Figures Legend
Figure 1 (a) and (b). Structure of PF-5190457 and Hydroxy metabolite.
Figure 2. Representative chromatograms of (a) drug-free plasma sample (b)
plasma sample extracted with IS and (c) plasma sample spiked at lower limit of
quantiﬁcation for PF-5190457 and hydroxy metabolite, and extracted with 2.5
ng/mL of tacrine respectively.
Figure 3(a). Chromatogram obtained with post column infusion shows no matrix
effect at the retention times of analytes and IS. Arrows indicates region where the
signal of compounds infused post-column is suppressed during the elution of
endogenous matrix components (b) Chromatogram showing the peaks of
analytes and corresponding IS along with key phospholipids.
Figure 4. Bland–Altman plots for (a). the correlation of PF-5190457 samples
(n=45) analyzed by LC-MS/MS by method 1 vs. the current LC/MS/MS Dashed
lines represent 95% limits of agreement (lower = −13.7%, upper = 13%) (b) and
(c) ISA (Incurred sample reanalysis) showing the correlation for original vs.
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repeat analysis for PF-5190457 (lower = −2.7%, upper = 22.7%) and hydroxy
metabolite (lower = −22%, upper = 11%) respectively.
Figure 5. Representative graph showing plasma concentration time profiles for
parent (PF-5190547) and hydroxy metabolite after the administration of 50 mg
dose respectively in a study volunteer.
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Table I-1.
Mass spectrometry parameters for analytes and IS
Compound Parent
Ion

Daughter Dwell

Cone

Collision Retention

ion (m/z)

(V)

energy

Time

(V)

(min)

(s)

(m/z)
PF-

513

209, 335

0.025

30, 30 44, 16

4.4

529

225, 351

0.025

34, 32 40, 20

3.8

199

170, 143

0.025

46, 42 30, 36

4.6

5190457
Hydroxy
metabolite
Tacrine
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Table I-2.
Summary of calibration standards from six validation runs
PF-

Nominal

5190457

Conc. (ng/mL)

STD 1

Mean

SD

% Bias

CV

%Accuracy

1

1

0

0.9

3.9

99.1

STD 2

2

1.9

0.2

-4.8

8.2

104.8

STD 3

10

11.2

0.4

12

3.7

88

STD 4

100

108.8

3.8

8.8

3.5

91.2

STD 5

250

266.8

8.4

6.7

3.2

93.3

STD 6

500

521.2

10.2 4.2

2

95.8

STD 7

800

822.3

20.5 2.8

2.5

97.2

STD 8

1000

936.4

20.3 -6.4

2.2

106.4

r2

0.997

Hydroxy

Nominal

metabolite

Conc. (ng/mL)

STD 1

0.2

Mean

SD

% Bias

CV

%Accuracy

2

2.1

0.1

3.4

5.8

96.6

STD 2

3.9

3.4

0.1

-12.9

2.5

112.9

STD 3

7.8

6.9

0.8

-11.7

12.2 111.7

STD 4

15.6

13.5

0.8

-13.2

5.8

111.6

STD 5

31.5

28.3

0.9

-10.1

3

110.1

STD 6

62.5

58.4

3.4

-6.6

5.7

106.6

STD 7

125

127.6

1.6

2.1

1.2

97.9

STD 8

250

256.7

2.4

2.7

0.9

97.3

r2

0.996

0.3

n=6 (one replicate for each of the six validation runs), %Accuracy=100−[(meannominal)/nominal] *100, %CV calculated as (SD/mean) *100, %bias calculated
as 100×(mean−nominal)/nominal
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Table I-3.
Summary of QC samples from six validation runs

Hydroxy metabolite

PF-5190457

Analyte

n=18

LLOQ

QC1

QC2

QC3

Nominal Conc (ng/mL)

1.0

3.0

200.0

750.0

Inter-run Mean

1.0

2.9

224.0

776.6

Inter-run SD

0.1

0.2

5.3

28.3

Inter-run % Bias

4.9

-4.2

12.0

3.5

Inter-run CV

11.4

7.6

2.4

3.6

%Accuracy

95.1

104.2

88.0

96.5

LLOQ

QC1

QC2

QC3

Nominal Conc (ng/mL)

2.0

5.0

25.0

200.0

Inter-run Mean

2.0

4.9

22.6

205.5

Inter-run SD

0.1

0.2

0.8

9.8

Inter-run % Bias

2.1

-2.6

-9.7

2.8

Inter-run CV

6.0

4.7

3.6

4.8

%Accuracy

97.9

102.6

109.7

(three

replicates

for

each

of

the

six

97.2

validation

runs),

%Accuracy=100−[(mean-nominal)/nominal] *100, %CV calculated as (SD/mean)
*100, %bias calculated as 100×(mean−nominal)/nominal
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Table I-4.

Hydroxy Metabolite

PF-5190457

Summary of stability studies
Bench top

Freeze thaw

Autosampler Short-term

(6h)

(3 cycles)

(36h)

LQC HQC

LQC

HQC

LQC

HQC

LQC

HQC

(1 week)

Mean

3.0

795.0 2.7

782.2

2.8

759.1

3.0

759.3

% Bias

0.3

6.0

-9.4

4.3

-5.3

1.2

-0.8

1.2

% CV

9.6

3.7

6.4

4.2

2.2

3.1

2.1

3.1

Mean

5.0

215.2 4.8

222.3

-1.5

211.0

4.2

220.0

% Bias

-3.9

7.6

-5.9

11.1

-3.3

5.5

1.0

10.0

% CV

7.7

2.8

7.0

0.9

8.2

3.8

4.6

0.8

%CV calculated as (SD/mean) *100, %bias calculated as
100×(mean−nominal)/nominal
LQC and HQC for PF-5190547and hydroxy metabolite are 3 and 750 ng/mL, 5
and 200 ng/mL respectively
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Figure I-1 (a) and (b). Structure of PF-5190457 and hydroxy metabolite
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28

29

Figure I-2. Representative chromatograms of (a) drug-free plasma sample (b)
plasma sample extracted with IS and (c) plasma sample spiked at lower limit of
quantiﬁcation for PF-5190457 and hydroxy metabolite, and extracted with 2.5
ng/mL of tacrine respectively.

30

31

Figure I-3(a). Chromatogram obtained with post column infusion shows no
matrix effect at the retention times of analytes and IS. Arrows indicates region
where the signal of compounds infused post-column is suppressed during the
elution of endogenous matrix components (b) Chromatogram showing the peaks
of analytes and corresponding IS along with key phospholipids
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Figure I-4 Bland–Altman plots for (a). the correlation of PF-5190457 samples
(n=45) analyzed by LC-MS/MS by method 1 vs. the current LC/MS/MS (b) and
(c) ISA (Incurred sample reanalysis) showing the correlation for original vs.
repeat analysis for PF-5190457 and hydroxy metabolite respectively. All the plots
indicate the percentage difference between the concentrations of analytes
measured were within ±20%.
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Figure I-5. Representative graph showing plasma concentration time profiles for
parent (PF-5190547) and hydroxy metabolite after the administration of 50 mg
dose respectively in a study volunteer.
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Abstract
PF-5190457

((R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimi-

din-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl) ethan-1-one),
was identified as a potent and selective ghrelin receptor inverse agonist. The
present study characterizes the routes of biotransformation of this compound in
vivo and then further explores in vitro metabolism using subcellular fractions of
human liver and primary hepatocytes. Following oral administration of PF5190457, hydroxyl metabolites were observed, including one that had not been
observed in human liver microsomal incubations. This major hydroxy metabolite
was biosynthesized using liver cytosol and the site of hydroxylation was shown to
be on the pyrimidine using nuclear magnetic resonance spectroscopy.

The

chemical inhibitors of AO (raloxifene) and XO (febuxostat) inhibited the formation
of the major hydroxy metabolite in human liver cytosol. Both the enzymes were
involved in the metabolism of the drug whereas, greater inhibition was observed
to be achieved using AO inhibitor indicating AO to be a dominant enzyme. The
Clint of the drug in human liver cytosol was 0.002 mL/min/mg protein. This study
demonstrates the importance of considering the molybdenum-containing
oxidases during the development of new drug entities.
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Introduction
Ghrelin is a 28 amino acid peptide released from the stomach fundus and has a
key role in growth and energy balance in the body (Korbonits et al., 2004). It is an
endogenous ligand binding to the growth hormone secretagogue receptor in the
hypothalamus resulting in increased food intake and decreased energy
expenditure (Kojima et al., 1999; Asakawa et al., 2001; Inui et al., 2004). Leptin
has an opposite effect to that of ghrelin and both the hormones together regulate
energy homeostasis in the body (Yildiz et al., 2004). Ghrelin is used as an
orexigenic agent to stimulate food intake as shown in clinical studies (Nagaya et
al., 2004; Neary et al., 2004; Nagaya et al., 2005). Moreover, intravenous ghrelin
administration suppresses glucose dependent insulin secretion in healthy
subjects (Tong et al., 2010). It has been observed that neurotransmitters and
peptides regulating food intake can also influence craving for alcohol in alcoholic
individuals (Leggio et al., 2011; Volkow et al., 2013). In a human study,
intravenous administration of ghrelin (3 mcg/kg in 45 subjects) increased the
craving towards alcohol in alcohol dependent heavy drinkers (Leggio et al.,
2014). Furthermore, in a rat study, it was demonstrated that antagonizing ghrelin
receptor could prove as a potential target to treat alcohol addiction (Suchankova
et al., 2013). Thus, inhibition of ghrelin and growth hormone secretagogue
system can potentially lead to the discovery of novel pharmacological treatments
for alcoholism.
PF-5190457 ((R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methyl-
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pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethan-1one; Fig. 1) is a member of spiro-azetidino-piperidine series identified as a potent
ghrelin receptor inverse agonist (Bhattacharya et al., 2014). It is presently
undergoing clinical trials at the National Institutes of Health for the treatment of
alcohol use disorder (Ghareeb et al., 2015; Kong et al., 2016). In healthy
volunteers, PF-5190457 was observed to be well tolerated (Denney et al., 2017)
and it was found to be safe in a phase 1b study in subjects with alcohol use
disorder (Lee et al, to be submitted for publication). The absorption of the drug
after oral administration was rapid with a Tmax of 0.3-3 h and the elimination halflife (t1/2) was found to be ~8 h (Denney et al., 2017).
Limited information is available on the biotransformation of PF-5190457.
The assessment of metabolic pathways of a new drug is important as it helps to
understand the pharmacokinetics and pharmacodynamics of the compound in
human. It is essential to identify the enzymes responsible for biotransformation,
as this information contributes to an understanding of interindividual variability in
pharmacokinetics that can be due to genetic polymorphism or drug-drug
interactions. In addition, metabolites generated by these enzymes could be
pharmacologically active or have off-target effects (Lin and Lu, 1997; Kumar and
Surapaneni, 2001).
The

objective

of

the

present

study

was

to

characterize

the

biotransformation of PF-5190457 in vitro and to identify the major human
circulating metabolites. Specifically, the objectives include 1) to characterize the
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circulating metabolites in vivo in human plasma, 2) to determine of formation of
metabolites in vitro, in sub-cellular fractions of human liver and human
hepatocytes, 3) to confirm the structure of identified metabolites by mass
spectrometry and NMR analyses 4) to assess the kinetic parameters of the
metabolite formation, and 5) to identify the enzyme/s responsible for the
formation of the major circulating metabolite using specific inhibitors for each
enzyme.

42

Materials and Methods
Reagents.
PF-5190457, raloxifene hydrochloride, febuxostat and tacrine (internal standard)
were purchased from Sigma Aldrich (St. Louise, MO, USA).

Allopurinol was

purchased from Toronto Research Chemicals (Toronto, Canada). PF-5190457
major hydroxy metabolite (also called PF-6870961) was biosynthesized as
described below. Recombinant aldehyde oxidase (rAOX) was produced by Pfizer
La Jolla, CA, USA). Dihydronicotinamide-adenine dinucleotide phosphate
(NADPH) tetrasodium salt was obtained from Calbiochem (EMD Millipore,
Billerica, MA). LC-MS grade methanol, acetonitrile and formic acid were
purchased from Fisher Scientific (Fairlawn, NJ, USA). All other reagents and
chemicals used in the study were of analytical grade and used without further
purification.

In Vivo Metabolite Profiling.
Study Samples.
Plasma samples obtained after oral administration of PF-5190457 from
phase 1b clinical study (NCT02039349) in alcoholic patients conducted at the
NIH Clinical Center (Bethesda, MD, USA) were analyzed by high-resolution mass
spectrometry (HRMS) to identify the circulating metabolites. The study was
approved by the University of Rhode Island Institutional Review Board HU#
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123.172. The participants have filled out the informed consent form prior to the
study.
Sample Preparation.
Pooled plasma samples from representative patients were prepared for
metabolite profiling experiments at various sampling times (predose, early and
late post dose). Plasma proteins were precipitated by methanol followed by
vortex mixing and centrifugation at 1,700 g for 5 min. The supernatant was then
transferred into a (Genevac, Valley Cottage, NY), evaporated for 4h, and then
reconstituted in 30 μL methanol followed by 120 μL water. The reconstituted
samples were spun in a microfuge for 3 min to remove particulates, and 10 μL of
aliquot of the reconstituted solution was injected onto HRMS system.
LC-TOF mass spectrometry
Chromatographic separation for metabolite profiling was achieved using a
Waters HSS T3 C18 column (1.8 μm; 2.1x100 mm; Waters Corp) connected to
Thermo Accela HPLC pump, CTC Analytics autoinjector, a diode array detector
(PDA or DAD) and a Thermo Orbitrap Elite high resolution mass spectrometer
(HRMS) (Thermo Fisher Scientific Inc, Waltham, MA, USA). The mobile phase
consisted of 10 mM ammonium acetate (A) and methanol (B) with a flow rate of
0.35 mL/min. The gradient elution was started from 5% B, maintained for 0.5 min,
increased to 50% B over 10 min, and then to 95% B over the next 2 min and
finally decreased to 5% B to re-equilibrate the column with a total run time of 15
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min. The MS detection was operated in positive ion electrospray (ES-positive)
mode.

In Vitro Biotransformation of PF-5190457
Preparation of subcellular fractions
Human liver tissues (n=104) were obtained from Xenotech (Lenexa, KS,
USA). Microsomal (HLM) and cytosolic (HLC) fractions were prepared by
differential ultracentrifugation from human liver as described previously (Jamwal
et al., 2017). Total protein concentration for the HLM and HLC were determined
using Pierce BCA (bicinchoninic acid) protein assay kit (Thermo Fisher Scientific
Inc, Waltham, MA, USA) and the fractions were stored in -80°C until further
analysis.
HLM and HLC Incubations
The in vitro metabolism of PF-5190457 was studied using HLM and HLC.
PF-5190457 was incubated at relatively high concentrations (50-100 µM) with
pooled HLM and HLC in a total volume of 50 µL of 100 mM potassium phosphate
buffer (pH-7.4) such that the final concentration of methanol was less than
0.25%. Incubations were conducted at 37°C in an oscillating water bath. The total
protein concentration used for both HLM and HLC ranged from 0.05 - 2 mg/mL.
PF-5190457 was also incubated in only 100 mM potassium phosphate buffer
(pH-7.4) without HLM or HLC as control. Microsomal incubations were conducted
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with and without the addition of NADPH. The reaction was terminated by addition
of 200 µL of ice-cold methanol at various incubation times (0-120 min).
Subsequently, the samples were centrifuged for 5 min at 10,000 rpm to remove
the precipitated protein.
LC-MS/MS analysis of HLM and HLC samples
The supernatant obtained from the samples was analyzed using an
Acquity UPLC coupled with a Xevo-TQ mass spectrometer (Waters Corp,
Milford, MA, USA). Samples (5 μL) were injected onto a C18 column (Acquity
UPLC BEH 2.1 x 50 mm) with 1.7 µm particle size and 130 Å porosity. A precolumn (Acquity UPLC BEH C18, 2.1 x 5 mm) was connected prior to the
analytical column. Mobile phase consisted of water: methanol 95:5% (v/v)
containing 0.1% formic acid (A) and 100% methanol containing 0.1% formic acid
(B). The column and autosampler temperature were kept at 40°C and 10°C,
respectively. The mobile phase was delivered at 0.25 mL/min flow rate and the
injection volume was 5 µL. Mobile phase initial condition of 98% solvent A, 2%
solvent B was maintained for 2 min, but proportion of solvent B was increased to
50% over 8.30 min, and then to 95% solvent B over the next 2 min and returned
to the initial condition for equilibration. The total run time was 12.30 min. A full
scan from 100-1200 Da was carried out in a positive electrospray ionization
mode with the following parameters: desolvation temperature of 600°C,
desolvation gas flow of 1000 L/h, capillary voltage of 3.50 kV and cone voltage of
30 V. Similarly, single-ion monitoring for the [M+H] + ions of the anticipated
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metabolites - hydroxy metabolite (513.2431+16), glucuronide (513.2431+176)
and hydroxy glucuronide (513.2431+192) conjugates with daughter scan was
performed.
Hepatocytes incubations
PF-05190457 was incubated in human hepatocytes with and without 1
amino benzotriazole (ABT) - a pan CYP450 inhibitor and hydralazine - a selective
probe inactivator of aldehyde oxidase (AO) respectively (Ortiz de Montellano and
Mathews, 1981; Strelevitz et al., 2012).
Incubations in liver cytosol of various species
PF-5190457 was incubated at 20 µM, with pooled mouse (male and
female), rat and monkey (male and female) liver cytosol (2 mg/mL) in a total
volume of 1 mL potassium phosphate buffer (100 mM; pH 7.5). Incubations were
performed at 37°C for 75 min and then stopped by addition of acetonitrile (5 mL).
Samples were centrifuged at 1700 g for 5 min and the supernatant was
evaporated in vacuo, reconstituted in 1% formic acid (0.2 mL) for analysis by
HPLC-UV-MS.

Biosynthesis and NMR Analysis
PF-5190457 (20 µM) was incubated with female mouse liver cytosol (20
mg/mL; Corning-Gentest, Woburn, MA) in 40 mL potassium phosphate buffer
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(100 mM, pH 7.5) in a shaking water bath maintained at 37 oC for 1.5 hr.
The incubation was terminated with addition of CH3CN (40 mL) and the
precipitated material was removed by spinning in a centrifuge for 5 min at 1,700
g. The supernatant was partially evaporated in a Genevac vacuum centrifuge for
2 hr. To the remaining mixture was added 0.25 mL neat formic acid, 0.25 mL
CH3CN, and water to a final volume of 25 mL. This mixture was spun in a
centrifuge at 40,000 g for 30 min. The clarified supernatant was applied to an
HPLC column (Polaris C18, 4.6 x 250 mm; 5µ particle size) through a Jasco
HPLC pump at a rate of 0.8 mL/min. After the entire sample was applied, an
additional ~5 mL of mobile phase (0.1% formic acid containing 1% CH3CN) was
pumped through the system. The column was moved to a Thermo LTQ HPLCMS system containing a photodiode array detector and a mobile phase gradient
was applied to elute material of interest. The mobile phase was comprised of
0.1% formic acid in water and CH3CN and was run at a flow rate of 0.8 mL/min.
The gradient began at a composition of 2%B for 5 min followed by a linear
gradient to 25%B at 70 min. The eluent passed through the photodiode array
detector scanning from 200-400 nm and then to a splitter (ratio was
approximately 15:1) with the larger portion going to a CTC Leaptec fraction
collector (CTC, Cary, NC).

Fractions were collected every 20 sec. The

remainder was introduced into the mass spectrometer operated in the positive
ion mode. The fractions proposed to contain the hydroxy metabolites of interest
were analyzed for identity and purity on a Thermo Orbitrap Elite UHPLC-UV-MS
system containing an Acquity column (HSS T3 C18, 2.1 x 100 mm, 1.7 µm
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particle size) using the mobile phases described above at a flow rate of 0.4
mL/min and an injection volume of 5 µL. The composition began at 5% solvent B
for 0.5 min followed by a gradient to 35% solvent B at 8 min, a second gradient to
95% solvent B at 10 min, and re-equilibration to initial conditions. Fractions
containing single peaks by UV and the desired protonated molecular ions were
combined and evaporated by vacuum centrifugation for analysis by NMR
spectroscopy. Later, the fraction was reconstituted with 100 µL of DMSO-d6 prior
to NMR analysis. NMR spectra were recorded on a Bruker Avance 600 MHz
instrument (Bruker BioSpin Corporation, Billerica, MA). The 1H, and 2D NMR (1H
COSY, HMBC, and HSQC) analyses were carried out in DMSO solutions of
analyte.

Enzyme Kinetic Studies
The formation of major hydroxy metabolite in rAOX and HLC was studied
to determine the enzyme kinetic parameters. Before the assessment of the
enzyme kinetics, protein concentration and incubation time for the kinetic studies
were evaluated to ensure the linearity of major hydroxy metabolite formation with
respect to protein concentration and time. It was also seen that substrate
utilization during the reaction was less than 10%.
rAOX incubations
PF-5190457 (0.5-125 µM) was incubated with rAOX (0.090 mg/mL) in 100
mM potassium phosphate buffer. The incubations were conducted at 37°C in
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shaking water bath. The incubation mixture volume was 50 µL and all incubation
samples were in triplicate. The reactions were terminated after 120 min using icecold methanol containing 2.5 ng/mL tacrine as IS.
Screening of allopurinol and oxypurinol in HLC.
The human livers utilized in this study were obtained from Sekisui
XenoTech LLC which is typically retrieved from brain dead individuals for organ
transplantation purpose but could not be transplanted. As such, the livers were
perfused with the University of Wisconsin Cold Storage Solution (UW) containing
allopurinol.

However, it is known that allopurinol and its primary metabolite

oxypurinol to be potent inhibitors of xanthine oxidase (XO) activity (Barr et al.,
2014).
To detect the presence the XO inhibitors, HLC (n=104) were tested for the
presence

of

allopurinol

and

oxypurinol

using

the

same

LC-MS/MS

instrumentation and mobile phases as described earlier in HLC and HLM
analysis. The flow rate was 0.3 mL/min, the column was equilibrated at initial
conditions of 90% solvent A for 1.2 min and then to 10% at 2 min. Over the next
minute, solvent A was increased to 90% and then kept constant for a reequilibration time for 3 min. The total chromatographic run time was 3 min per
sample. The multiple reaction monitoring (MRM) transitions used for allopurinol
and oxypurinol detection were 137.1/110.1 and 153.1/136.1 respectively.
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HLC incubations
Kinetic parameters for the formation of the major hydroxy metabolite from
PF-5190457 was determined by incubating the drug in pooled, allopurinol and
oxypurinol free, HLC. The optimized total protein concentration and incubation
times in HLC was 0.1 mg/mL and 5 min, respectively. PF-5190457 (0.05–100
μM) with HLC in a total volume of 50 µL of 100 mM potassium phosphate buffer
(pH-7.4) were incubated at 37°C in duplicate. The final concentration of methanol
in the incubations was less than 0.25%. The reaction was initiated by the addition
of cytosol. Incubations (50 µL) were terminated by protein precipitation with the
addition of methanol (200 µL) containing the 2.5 ng/mL IS.
LC-MS/MS analysis for kinetic studies
All the samples from rAOX and HLC were centrifuged for 5 min at 10,000
rpm. The supernatants were removed and analyzed. The parent, metabolite and
IS were monitored using Acquity UPLC system (Waters Corp., Milford, MA,
USA) coupled to Xevo TQ-MS (Waters Corp., Milford, MA, USA). The analytes
were separated using an aquity UPLC BEH C18 (2.1 x 50 mm, 1.7 µm particle
size, 130Ǻ pore size) analytical column with an Acquity UPLC BEH C18
VanGuard pre-column (2.1 x 5 mm, 130Ǻ). Mobile phase solution A consisted of
water: methanol 95/5 % (v/v) and mobile phase solution B consisted of methanol
(100%). Formic acid (0.1%) was added to both the mobile phase solutions. The
flow rate was 0.25 mL/min with a 10.30 min run time. The column temperature
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was maintained at 40°C. The gradient consisted of 2% methanol for 2 min,
increased to 35% for 2.0 - 7.30 min, further increased to 95% methanol till 8 min
and held until 8.30 min before returning to initial conditions to equilibrate with a
total run time of 10.30 min. Mass spectral analysis and quantification was carried
out using MRM on a positive electrospray ionization mode with the following
parameters: desolvation temperature of 350°C, desolvation gas flow 650 L/h,
capillary voltage 3.50 kV and cone voltage 20 V. The optimized settings of mass
spectrometer voltage and the retention time (Rt) for the analytes and IS with
quantifier and qualifier fragments are summarized in Table 1. Data acquisition
and processing were performed using MassLynx™ software (V 4.1) and
TargetLynx™ tool respectively. Retention times for hydroxy metabolite and
internal standard were 4.4 and 5.1 min, respectively. Quantitation was done
using a hydroxy metabolite standard curve ranging from 0.1-1 µM. The
calibration standards were within ± 15% of nominal values.

Inhibition Studies
Incubation of PF-5190457 in HLC (with AO and XO inhibitors)
PF-5190457 (25 µM) was incubated with pooled allopurinol/oxypurinol free
HLC (n=9) in a total volume of 50 µL of 100 mM potassium phosphate buffer (pH7.4) in the presence and absence of inhibitors. Incubation conditions were similar
to previous HLC kinetic experiments. To identify the enzymes involved in the
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formation major hydroxy metabolite, HLC was incubated with and without AO
inhibitor (raloxifene 0.005-50 µM), and XO inhibitor (febuxostat 0.001-50 µM).
The reactions were terminated at 5 min using methanol containing 2.5 ng/mL
tacrine as internal standard (IS). The samples were analyzed using LC-MS/MS
as described under enzyme kinetic studies.

Data Analysis
Estimations of the maximum rate of major hydroxy metabolite formation
(Vmax) and the Michaelis-Menten constant (Km) were performed using nonlinear
regression analysis within GraphPad Prism (GraphPad Software Inc., La Jolla,
CA) using the Michaelis-Menten equation given below.
V = (Vmax*S)/(Km+S)
The apparent in vitro intrinsic clearance (Clint) was calculated as Vmax/Km.
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Results
Characterization of PF-5190457 Metabolites in Human Plasma
The circulating metabolites of PF-5190457 were determined in the plasma
of human subjects who were administered PF-5190457 orally in a phase 1b
clinical study (Fig. 2). Two peaks with protonated molecular ions of 16 mass units
greater than PF-5190457 were observed (m/z 529.2382), indicating the addition
of oxygen. Fragment ions of the hydroxyl metabolite that had a greater ion
abundance included m/z 351.2179, 305.1430, and 225.1022 (Fig. 3) which is
indicative of an oxidative biotransformation on the indenyl-pyrimidine portion of
the molecule. Additional metabolites proposed as glucuronide and hydroxy
glucuronide conjugates (m/z 689 and 705) were detected at apparent lower
levels in the plasma.

In Vitro Biotransformation of PF-5190457
HLM and HLC
Preliminary experiments conducted in the subcellular fractions of the
human liver generated the major hydroxyl metabolite in HLC without the addition
of cofactors. The metabolite formed in HLC increased with incubation time,
concentration of substrate, and concentration of cytosol. The hydroxy metabolite
was detected in HLC as the protonated molecular ion [M + H] + at m/z 529.
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Fragmentation of this ion produced fragments at m/z 225 and 351 (Fig. 4). This
metabolite was not observed in HLM supplemented with NADPH.
Hepatocytes
The formation of hydroxyl metabolites of PF-5190457 was observed in
human hepatocytes as shown in the chromatogram (Fig. 5). The traces were
extracted ion chromatograms of m/z 529.2376 (5 ppm tolerance) representing
the protonated molecular ion of a hydroxylated metabolite. The addition of ABT, a
broad-spectrum P450 inactivator inhibited the formation of the apparent minor
metabolites at Rt 4.12, 4.62, and 5.57 min and had no effect on the metabolite
eluting at Rt 3.98 min suggesting that CYP mediated metabolism for the minor
metabolites and not the major metabolite. It was also observed that addition of
hydralazine inhibited formation of the metabolite at Rt 3.97 min indicating that AO
could be responsible for the generation of this metabolite.
Incubations in liver cytosol from various species
The formation of hydroxy metabolite (513+13) was observed in cytosolic
incubations of PF-5190457 in mouse (male and female), rat (male), monkey
(female) indicating the metabolism to be independent of NADPH (Fig. 6). The
hydroxy metabolite formed in cytosol of various species had similar retention time
to that of the metabolite formed in HLC.

55

NMR Analysis
Characterization of biosynthesized hydroxy metabolite by NMR analysis
demonstrated that the site of hydroxylation was on the carbon between the
nitrogen on the 4-methylpyrimidine moiety (Fig. 7). 1H COSY, HMQC, and HMBC
spectra were obtained to support the hydroxylation of pyrimidine moiety
(Supplemental data Fig. 2, 3 (a) and (b)).

Enzyme Kinetic Analysis
The HLC that were free (n=9) of allopurinol and oxypurinol were pooled
together for further kinetic and inhibition experiments. The kinetics for the
formation of major hydroxy metabolite from PF-5190457 was determined by
incubating in rAOX and HLC. Representative Michaelis-Menten kinetic plots in
rAOX and HLC are depicted in Fig. 8 and Fig. 9. Substrate inhibition kinetics at
higher concentration of substrate was observed for rAOX incubations. The Km
and Vmax values for the formation of hydroxy metabolite in rAOX and HLC were
found to be 6.9 μM and 0.35 nmol/min/mg protein and 42 μM and 0.12
nmol/min/mg protein respectively. The Clint in rAOX and HLC were 0.05 and
0.002 mL/min/mg protein respectively.

Biotransformation of PF-5190457 is mediated by AO and XO
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The effect of AO (raloxifene) and XO (febuxostat) inhibitors on the
metabolism of PF-5190457 was investigated. There was considerable (>75%)
but not complete inhibition of formation of the major hydroxy metabolite with 50
µM raloxifene (Fig. 10a). The extent of inhibition with febuxostat was greater than
50% at 1 µM (Fig. 10b) and further increases in inhibitor concentration did not
inhibit the formation of metabolite.
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Discussion
Characterization

of

circulating

metabolites

from

patients

orally

administered with PF-5190457 revealed the biotransformation pathways for this
ghrelin receptor inverse agonist. The primary route of metabolism observed in
humans was hydroxylation yielding a major hydroxy metabolite of PF-5190457).
In vitro experiments showed that this metabolite was generated in human liver
cytosol. The metabolite profiling of major circulating metabolite (m/z 529a) in
human plasma and the metabolite formed in HLC (m/z 529) showed similar
MS/MS fragmentation pattern (m/z 225, m/z 351) suggesting hydroxylation on
the pyrimidine ring yielding strong correlation between in vivo and in vitro data.
Results from these experiments suggest that primary biotransformation process
is non-NADPH-dependent metabolism in HLC leading to the formation of a
hydoxy pyrimidine metabolite. The formation of the metabolite by NADPH
independent process in HLC and the site of hydroxylation position on the PF5190457 confirmed from NMR analysis suggested the involvement of
molybdenum co-factor containing enzymes like AO and/or XO mediated
biotransformation. The position of hydroxylation on the pyrimidine ring between
the two nitrogen atoms suggests nucleophilic attack via AO and/or XO enzymes
in the metabolism of the drug (Krenitsky et al., 1972; Beedham, 1985; Kitamura
et al., 2006). In contrast to electrophillic oxidation by CYP450 enzymes, both AO
and XO enzymes display nucleophilic attack on carbon atom which is electron
deficient or carbon adjacent to N-heterocycle (eg. purines, pyrimidines and
pteridines) resulting in the formation of distinct metabolites (Krenitsky et al.,
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1972). Furthermore, the use of inhibitors indicated contribution of both AO and
XO enzymes to the formation of hydoxy pyrimidine metabolite of PF-5190457.
The data also suggest AO as a dominant enzyme in comparison to XO in the
biotransformation of PF-5190457.
AO and XO enzymes belong to a family of molybdo-flavoenzymes and
have a high level of similarity between their amino acid sequence homology
(Beedham, 1987; Terao et al., 2000; Hille, 2005). XO can exists as two
interconvertible forms as xanthine oxidase and xanthine dehydrogenase unlike
AO (Della Corte et al., 1969). AO was found to be one of the highly abundant
enzymes in HLC and the expression of AO was greater in comparison to XO in
human liver (Nishimura and Naito, 2006; Sodhi et al., 2015).

Physiological

relevance of AO is still not known but XO plays an important role in catalyzing
hypoxanthine to xanthine and later to uric acid (Beedham, 1985; Kitamura et al.,
2006). Both the enzymes differ in substrate and inhibitors specificity. Increasing
number of substrates in the past few decades have been identified to be
catalyzed by the two enzymes especially involving AO which also has broader
substrate specificity in comparison to XO (O'Connor et al., 2006; Pryde et al.,
2010; Sanoh et al., 2015; Battelli et al., 2016). There are only few substrates
which show biotransformation by both the enzymes like 6-deoxyclovir, 6thioxanthine, and recently VU0409106 a lead compound for childhood
developmental disorders (Krenitsky et al., 1984; Morrison et al., 2012; Choughule
et al., 2014). Though some overlap exists between the substrates, there has
been various panel of chemical inhibitors identified specifically for AO and XO
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inhibitors including raloxifene (Obach, 2004), hydralazine (Strelevitz et al., 2012),
allopurinol (Panoutsopoulos et al., 2004) and febuxostat (Weidert et al., 2014).
Allopurinol has been widely used as a known XO inhibitor but recently it was
identified that febuxostat is a more potent inhibitor of XO than allopurinol (Malik
et al., 2011). There are not any important clinical drug-drug interactions
associated with inhibition of AO but as growth in new chemical entities
metabolized by AO is increasing, there could arise a need to characterize in
drug-drug interaction potential at AO level (Obach, 2004; Pryde et al., 2010). It is
a challenge to capture the drug interactions associated with these enzymes
especially for AO enzyme in animal models as there exist species differences for
expression and activity along with disparity with gender and strain (Itoh, 2009;
Crouch et al., 2017; Mao et al., 2017).
Both potent XO inhibitors, allopurinol and febuxostat are clinically used for
treatment of chronic gout and hyperuricemia. This condition is also present in
disease states like metabolic syndrome, diabetes, chronic liver disease and
cardiovascular disease (Hu and Tomlinson, 2008; George and Minter, 2017)
some of which are target population for PF-5190457. There have been drug-drug
interactions reported in man through the inhibition of XO substrates. For
example, in one clinical study, allopurinol significantly inhibited 6-mercaptopurine
which is a substrate for XO when administered orally and there was significant
increase in peak plasma concentration and area under the curve of 6mercaptopurine in patients with acute lymphoblastic leukemia (Zimm et al.,
1983).
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Inter-individual variability between donors has been observed in in vitro
studies for hepatic AO and XO activity (Guerciolini et al., 1991; Al-Salmy, 2001;
Hutzler et al., 2014). However, single nucleotide polymorphisms in the AO and
XO genes has not been extensively studied in various populations (Levartovsky
et al., 2000; Gok et al., 2003; Hutzler et al., 2014). Genetic polymorphism of AO
gene was studied in an Italian study and the presence of both fast and poor
metabolizers was observed (Hartmann et al., 2012). Moreover, two in vitro
studies showed genetic variation in the XO gene could be responsible in
individual variations in XO activity (Kudo et al., 2008; Kudo et al., 2010). A
recent study in European population suggests that XO variants had influence on
uric acid production since XO also catalyzes uric acid production (Scheepers et
al., 2016).
Both in vitro and in vivo studies recognized the hydroxy pyrimidine
metabolite as the major metabolite of PF-5190457. The findings presented here
shows that both AO and XO contribute to the metabolism of PF-5190457
resulting in the formation of a major circulating metabolite. The study also
emphasizes the importance of these non-CYP enzymes in the drug metabolism
during the early stages of drug development. The kinetics of PF-5190457 in
rAOX and HLC gave an impression on the sub saturation concentrations in the
allopurinol free livers. The data and the experimental conditions could be used in
the future to investigate the Clint to study the effect of various factors like age,
gender, smoking, alcohol use or disease states to improve the clinical
pharmacokinetics and efficacy of the drug in that respective population.
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The pharmacokinetic profile of the PF-5190457 and its major hydroxy
metabolite has been investigated in plasma samples obtained from human
subjects during the phase 1b study which is described elsewhere (Manuscript
IV). It is important to identify the other metabolic pathways and route of
elimination of PF-5190457 in the context of a mass balance study.
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Legend for Tables
Table II-1. Mass spectrometry parameters for analytes and IS
Parent
Compound

Collision

Retention

energy

Time

(V)

(min)

30, 30

44, 16

5.6

0.025

34, 32

40, 20

4.5

0.025

46, 42

30, 36

5.9

Daughter

Dwell

Cone

Ion (m/z)

(s)

(V)

513

209, 335

0.025

529

225, 351

199

170, 143

ion
(m/z)

Parent
drug (PF5190457)
Major
hydroxy
metabolite
Internal
standard
(tacrine)
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Legend of Figures
Fig. 1. Structure of PF-5190457
Fig. 2. Metabolic profiles of pooled patient plasma samples at various sampling
times (predose, early and late times) after administration of PF-5190457
analyzed by HPLC-UV and HPLC-MS/MS (representative m/z of the detected
metabolites).
Fig. 3. Full scan and daughter ion scan of the major metabolite 529a detected at
7:30 min in the pooled human plasma samples.
Fig. 4. Representative mass spectra in HLC. (a) Experimental PF-5190457
incubation sample in HLC (b) Blank cytosol without the addition of substrate
Fig. 5. HPLC-MS traces for PF-5190457 incubated in pooled human hepatocytes
Fig. 6. HPLC-MS traces for PF-5190457 incubated in liver cytosol various
species.
Fig. 7. 1H Proton NMR Spectra of hydroxy metabolite of PF-5190457
Fig. 8. Representative kinetics for the metabolism of PF-5190457 to hydroxy
metabolite in recombinant aldehyde oxidase incubations.
Fig. 9. Representative kinetics for the metabolism of PF-5190457 to hydroxy
metabolite in human liver cytosolic incubations.
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Fig. 10. Hydroxy metabolite formation in the presence of inhibitors (% of control)
at various concentrations of, (a) raloxifene and (b) febuxostat with 25 µM PF5190457 in human liver cytosolic incubations.
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Fig. II-1. Structure of PF-5190457

Fig. II-2. Metabolic profiles of pooled patient plasma samples at various sampling
times (predose, early and late) after administration of PF-5190457 after HPLCUV and HPLC-MS/MS analysis (representative m/z of the detected metabolites).
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Fig. II-3. Full scan and daughter scan of the major metabolite 529a detected at
7:30 min in the pooled human plasma samples.

Fig. II-4. Representative mass spectra in HLC. (a) Experimental PF-5190457
incubation sample in HLC (b) Blank cytosol without the addition of substrate
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Fig. II-5. HPLC-MS Traces for PF-5190457 incubated in pooled human
hepatocytes. Peaks at Rt of 4.12, 4.62, and 5.57 min (denoted with blue arrows)
were sensitive to ABT. The peak eluting at 3.97 min (denoted with red arrows)
was insensitive to ABT but was inhibited by hydralazine.
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Fig. II-6. HPLC-MS Traces for PF-5190457 incubated in liver cytosol various
species. Peaks at Rt of 3.12 and 3.61 min represents hydroxylated metabolite
(513+16) and parent drug respectively.
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Fig.II-7. 1H Proton NMR Spectra of hydroxy metabolite of PF-5190457
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Fig. II-8. Representative kinetics for the metabolism of PF-5190457 to hydroxy
metabolite formation in recombinant aldehyde oxidase incubations. Increasing
concentrations of PF-5190457 (0.52 – 125 μM) were incubated with recombinant
aldehyde oxidase (0.090 mg/mL) for 120 min at 37°C. Formation rates of
metabolite (nmol/min/mg protein) versus PF-5190457 concentration (μM) were
best-fit using nonlinear-regression analysis.
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Fig. II-9. Representative kinetics for the metabolism of PF-5190457 to hydroxy
metabolite in human liver cytosolic incubations. Increasing concentrations of PF5190457 (1.5 – 400 μM) were incubated with human liver cytosolic samples (0.1
mg/mL) for 5 min at 37°C. Formation rates of metabolite (nmol/min/mg protein)
versus PF-5190457 concentration (μM) were best-fit using non-linear regression
analysis
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Fig. II-10. Hydroxy metabolite formation in the presence of inhibitors (% of
control) at various concentrations of, (a) raloxifene and (b) febuxostat with 25 µM
PF-5190457 in allopurinol free (n=9) pooled human liver cytosolic incubations.
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Supplemental Data
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Supplemental Fig II-1 Shows percentage of PF-5190457 hydroxy metabolite
formed in the presence and absence of inhibitors at various concentrations of (a)
hydralazine, (b) allopurinol; the incubations contained 25 µM PF-5190457 in
allopurinol free (n=9) pooled human liver cytosolic fraction
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Supplemental Fig. II-2. COSY: Black Curves HMBC: Red Curves

Supplemental Fig II-3a and b. COSY NMR Spectra and HSQC NMR Spectra of
hydroxy metabolite supporting oxidation at pyrimidine moiety
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Abstract
The present study describes the use of a mass spectrometry based label-free
quantification approach to estimate the expression of aldehyde oxidase protein
(AOX1) and also, to study the impact of various demographic factors on this
enzyme in liver cytosolic fractions in a well-characterized bank of human liver (n
= 104). Trypsin was used to digest cytosolic fractions, and a faster (90 min)
digestion method was aided by a pressure cycling technology. Tryptically
digested peptides were separated on an Acquity UHPLC Peptide BEH C18
column. The total run time was 60 min using a gradient method at a ﬂow rate of
0.1 mL/min. The HLC samples were analyzed using two acquisition methods by
data-dependent acquisition (DDA) and SWATH-MS (sequential windowed
acquisition of all theoretical fragment ion mass spectra) mode on quadrupoletime-of-ﬂight

mass

spectrometer

(ESI-QTOFMS)

operated

in

positive

electrospray ionization mode. SWATH-MS data extracted using Skyline (targeted
proteomics data extraction software) generated values for relative quantification
while absolute protein of AOX1 was calculated by MaxQuant (identification and
quantitative proteomics software) using total protein approach. We found that
results from SWATH-MS based acquisition were comparable to traditional DDA
method. The AOX1 levels quantified using MaxQuant was found to be in the
range of 2 - 49 pmol/mg cytosolic protein (19.5 fold), which are well comparable
to published reports on the expression of the enzyme. The effect of demographic
factors such as age, gender, ethnicity, smoking, drug use, alcohol consumption
and disease condition like diabetes and non alcoholic fatty liver disease (NAFLD)
83

on AOX1 protein in individual HLC were studied, but no significant association
was found. The reasons for observed variability could be because of other
underlying and unknown factors which show a need for further studies on the
enzyme.

Abbreviations
AO aldehyde oxidase, AOX1 human aldehyde oxidase protein, DDA Data
dependent

acquisition,

DIA

Data

independent

acquisition,

SWATH-MS

Sequential windowed acquisition of all theoretical fragment ion mass spectra, XO
Xanthine Oxidase
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Introduction
Aldehyde oxidase (AO), along with xanthine oxidase (XO), belongs to the family
of molybdo-flavoenzyme or molybdenum co factor containing enzymes and does
not require NADPH as a cofactor for oxidation (Beedham, 1985; Hille, 2005).
Unlike XO which catalyzes uric acid, the physiological function of AO in not
known yet (Kitamura et al., 2006). In the recent year, AO is gaining significance
in drug discovery programs because of a consorted effort to reduce the
contribution of cytochrome P450 (CYP450) mediated biotransformation to the
elimination of new drugs, (Pryde et al., 2010; Rashidi and Soltani, 2017). The
new drug molecules are designed to have nitrogens in their rings like purines
pyrimidines and pteridines to enable aldehyde oxidase metabolism (Lepri et al.,
2017; Paragas et al., 2017). In contrast to electrophilic attack by CYP450
enzymes, aldehyde oxidase follows nucleophilic attack using the oxygen from the
water (Beedham, 1985; Garattini et al., 2003). Various isoforms AOX1, AOX3,
AOX3L1, and AOX4, have been identified with species differences. The
functionally active aldehyde oxidase that is expressed in the human liver cytosol
as AOX1 along with two other pseudogenes AOX3 and AOX3L1 (Kurosaki et al.,
2013).
While a limited number of studies are published assessing the AOX1
levels in HLC, it is known that a significant degree of variability is associated with
the expression of this enzyme (Barr et al., 2013; Fu et al., 2013). In one of the
studies, the AOX1 levels reported in three batches of pooled HLC was found to
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be between 2 - 40 pmol/mg (20 fold) (Barr et al., 2013). The other study
assessed the levels in 20 individual HLC donors and the results observed were
much tighter ranging from 0.74 – 2.30 pmol/mg (~3 fold) (Fu et al., 2013). The
variation between both the studies was observed to be about 17 – 28-fold. Both
the studies mentioned above used the absolute method of quantification (MRM)
using mass spectroscopy.
The use of mass spectrometry is gaining popularity over traditional
methods, such as Western blotting, enzyme-linked immunosorbent assays
(ELISAs) and reverse-transcriptase polymerase chain reactions (RT-PCR) to
monitor or quantify the expression of proteins (Han et al., 2008; Aebersold et al.,
2013).

Label-Free

relative

quantiﬁcation

approach

for

studying

protein

abundance of metabolizing enzymes in biological samples using mass
spectrometry acquisition methods like data independent acquisition (DIA) and
data dependent acquisition (DDA) (or information dependent acquisition) have
been explored in the recent years (Hopfgartner et al., 2012). Our lab has recently
published on using sequential windowed acquisition of all theoretical fragment
ion mass spectra (SWATH-MS-MS), which is a DIA method, to study relative
quantification of enzymes using a label free approach (Jamwal et al., 2017).
In the present study, we used the DDA, and SWATH-MS to quantify the
relative expression of AOX1 protein in the human liver cytosol. The main
objective of the study was to quantify the AOX1 levels in a novel bank of human
liver and to study the effect of various demographic factors on AO protein
expression.
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Materials and Methods
Chemical and Reagents. Trypsin digested β-galactosidase (E. coli), protein
preparation

kit,

and

L-1-p-Tosylamino-2-phenylethyl

chloromethyl

ketone

(TPCK)-treated trypsin were purchased from Sciex (Framingham, MA). Mass
spectrometry grade acetonitrile and formic acid were from ThermoFisher
Scientiﬁc (Waltham, MA). Acquity UHPLC Peptide BEH C18 analytical column
and VanGuard precolumn were from Waters Corp. (Milford, MA).
Human liver bank.
Human liver tissue (N=104) was purchased from Sekisui XenoTech LLC
(Kansas City, KS). The livers were well characterized for age, gender, ethnicity,
the cause of death, cold ischemia time, liver and body weight, smoking, alcohol
consumption, diabetes and NAFLD. The information was available for ≥95% of
the samples.
HLC Preparation and Digestion.
Preparation of HLC and digestion of the samples was performed as
described previously (Jamwal et al., 2017). Brieﬂy, human liver samples were
homogenized using a bead homogenizer (Bead Ruptor 24, Omni International,
Kennesaw, GA). Ultracentrifugation was done to separate microsomes and
cytosol. The cytosolic fraction thus obtained was stored in -80°c for future use.
Cytosolic protein concentration was estimated using a bicinchoninic acid method
(Pierce-Fisher, Rockford, IL) with bovine serum albumin as a standard. The
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samples were diluted to 2.5 mg/mL in phosphate-buﬀered saline (pH 7.4) before
protein digestion. The samples (150 µg of cytosolic protein) initially were
denatured to disrupt the hydrogen and hydrophobic bonds of the proteins.
Subsequent steps were to reduce the disulfide bonds of the proteins and
addition of an alkylating agent to block the cysteine group in the samples. The
digestion buffer was added to the cysteine blocked samples to maintain the
optimum pH before digesting the samples. The proteins in the samples were
digested with TPCK treated trypsin (1:20 enzyme/protein) in a Barocyler
NEP2320− 45k (Pressure BioSciences Inc.) working on the principle of
pressure aided digestion of proteins (pressure cycling technology-PCT). The
optimized settings for temperature, cycles and pressure on the barocycler were
50 °C for 90 cycles, 50 s at 35 kpsi and 10 s at ambient pressure for every
cycle. Two technical replicates for each HLC sample were digested and
analyzed by mass spectrometry. XTreme 200 pool of HLC sample was used as
digestion control to monitor the batch-to-batch variation of protein digestion
carried out in six batches. Mostly, 12 cytosolic samples and one XTreme 200
pool of HLC as control sample were digested and run in every batch.
LC-QTOF/MS Analysis.
All the cytosolic digested samples were analyzed on a SCIEX 5600
TripleTOF mass spectrometer equipped with a DuoSpray ion source (SCIEX,
Concord, Canada) coupled to Acquity UHPLC HClass system (Waters Corp.,
Milford, MA, USA) which has a with a binary pump and a built-in column heater.
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Mass spectral analysis was carried out using a positive electrospray ionization
mode. Chromatography separation of peptides was accomplished within 11.30
min using gradient elution method using an Acquity UHPLC Peptide BEH C18
(2.1 × 150 mm2, 300 Å, 1.7 μm) analytical column. An Acquity VanGuard
precolumn (2.1 × 5 mm 2, 300 Å, 1.7 μm) was used prior to the analytical
column. The analytical column and autosampler temperature consisting digested
samples were kept at 40 °C and 10°C, respectively. Mobile phase A consisted of
98% water, 2% acetonitrile containing 0.1% formic acid and mobile phase B 98%
acetonitrile, 2% water containing 0.1% formic acid. The mobile phase was
delivered at 100 μL/min flow rate with a gradient method and total run time of 60
min. The initial conditions of mobile phase composition are as follows: (98% A)
was maintained for 3 min, 60% to 90% A from 3 to 48 min, and 20% A held till 52
min and returned to initial conditions for equilibration. The amount of protein per
injection on the column was 10 μg. In each batch, Trypsin-predigested betagalactosidase peptides were injected (∼30 pmol/injection) as quality control
every 10 samples during the analysis to monitor mass calibration of the TOF
detector and normalization of intensity during relative quantiﬁcation of AOX1
protein (described below). The average intensity of the β-galactosidase peptide
(APLDNDIGVSEATR) in a batch was used for data normalization of the
respective batch of samples.
DDA and SWATH-MS Data Acquisition Settings.
Two acquisition methods, DDA and SWATH-MS method were used to
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identify and quantify AOX1 protein. Analyst TF 1.7 was used to acquire data
during the study (SCIEX, Framingham, MA). The detailed settings for source and
compound parameters for both the acquisition methods are as described in
previously published paper from our lab (Jamwal et al., 2017). The DDA
experiments were performed in positive resolution mode over a mass range of
m/z 350−950 with a charge state 2 to 4, and quadrupole resolution of 0.7 AMU
were used for automated MS/MS analysis. Whereas, SWATH-MS-MS. based
spectra were acquired for mass range m/z 400−900 Da with SWATH-MS window
width of 25 m/z resulting in 20 overlapping mass windows per cycle.
Raw Data Processing.
Generation of spectral reference library
The data files of HLC samples obtained from the DDA acquisition were
analyzed

using the database

search engine

ProteinPilot

5.0

(SCIEX;

Framingham, MA, USA) The data were searched against the UniProt protein
database. The search was specified using the following parameters in the
Paragon method: sample type - identification; cysteine alkylation - MMTS;
digestion - Trypsin; instrument - TripleTOF 5600, species - Homo sapiens;
search effort -thorough and false discovery analysis - none.
Method 1 Based on DIA-SWATH-MS MS and Skyline analysis.
The spectral library generated from DDA ﬁles was uploaded in Skyline to
identify AOX1 protein, and SWATH-MS data ﬁles were processed using the full
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scan MS/MS ﬁltering at a resolution of 10000. Three unique AOX1 peptides were
identified and curated for reproducible fragment ions. The total area of
representative peptides for AOX1 protein was summed, and resulting intensity
was normalized by total intensity of tryptic peptide of β-galactosidase. MultiQuant
v 3.0 (SCIEX, Framingham, MA) was used to retrieve intensity for
APLDNDIGVSEATR peptide and was subsequently used for normalization
among diﬀerent batches as described above (Nakamura et al., 2016).
Method 2 Based on DDA acquisition and MaxQuant analysis.
The raw data files obtained from DDA data was analyzed for AOX1 using
MaxQuant (Version 1.5) and was searched against UniProt human protein
database at a false discovery rate (FDR) of 0.01. The absolute protein
concentration was calculated from label-free quantification (LFQ) intensities
using “Total Protein Approach”(Wisniewski and Rakus, 2014).
Statistical analysis.
Statistical analysis was performed with SPSS version 24 (IBM Analytics,
Armonk, NY), and Prism® version 6 (GraphPad Software Inc., San Diego, CA)
was used for graphs. Non-parametric Mann-Whitney U test and Kruskal-Wallis
test (2-tailed) were used to study the effect of three or more groups.

The

correlation was studied using nonparametric Spearman correlation analysis. P
<0.05 was considered significant for all the statistical tests and correlation
analysis.

91

Results
SWATH-MS based relative AOX1 levels
Three

unique

peptides

for

AOX1

protein

DILADVVQK,

MIQVVSR,

GTSTETVPNANISGGSVVADLNGLAVK and three fragment ions per peptide for
the protein were identified. AOX1 levels from SWATH-MS files are represented
after normalization Selected peptides for the relative quantiﬁcation of the AOX1
protein were correlated with each other and also, with sum of the three peptides
to validate the selection of peptides (Fig 1a and b). The correlation between the
surrogate peptides (Spearman, r = 0.94, p<0.0001) was significant. Likewise, the
correlation between one of the selected peptides (DILADVVQK) of AOX1 and
sum of the peptides was significant (Spearman, r = 0.98, p<0.0001). Two other
peptides had similar significant correlation (data not shown) generating
confidence in the selection of peptides.
DDA based absolute AOX1 levels
The AOX1 levels in the cytosolic samples determined via total protein
approach ranged from 2.46 – 49.02 pmol/mg cytosolic membrane protein. There
was variability with about 19-fold difference between the samples. Fig 3 shows
the distribution of AOX1 levels across various cytosolic samples. AOX1 levels
obtained via MaxQuant were used to determine the effect of various
demographic factors on the AO enzyme.
Correlation between SWATH-MS and DDA based results

92

The correlation between the AOX1 levels measured via both the
acquisition methods (DIA and DDA) was significant (Spearman, r = 0.72,
p<0.0001) (Fig 3). The results indicate the reliability of either of the acquisition
methods for determination of AOX1 levels.
Effect of demographic factors on AOX1 levels.
The effect of various factors like gender, age, weight, drug usage,
ethnicity, smoking, alcohol consumption along with disease conditions like
diabetes and NAFLD (non alcoholic fatty liver disease) was evaluated on AOX1
levels.
Cytosolic fatty acid synthase (FAS). FAS is observed to be a diagnostic marker
for progression in NAFLD (Dorn et al., 2010). As the disease progresses, the
FAS expression is expected to increase as seen in Fig 4. This enzyme was used
as a positive control to determine the quality of data generated from mass
spectroscopy.
Effect of Ethnicity.
The number of African American, Caucasian and Hispanic included in this
study are as shown in Table 1.

In general, African Americans exhibited

marginally higher AOX1 levels in comparison to Caucasian and Hispanic donors.
However, no significant association (P>0.4) was observed between Ethnicity and
AOX1 levels (Fig 5) (Table. 2).
Effect of Alcohol.
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Alcohol consumption in the liver donors were evaluated and scores were
determined based on the drinking scale (None = 0, Safe = 1, Moderate = 2,
Heavy = 3). The trend of AOX1 levels decreased with increase in alcohol
consumption but not significant (P>0.4) (Fig 5) (Table.2)
Effect of other demographic factors.
Other demographic factors such as gender, age, weight, drug usage,
smoking, along with disease conditions like diabetes and NAFLD (non alcoholic
fatty liver disease) were not detected to have an impact on AOX1 levels based
on our results. Table. 2 shows the effect of selected demographic factors on
AOX1 with mean ±SE
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Discussion
The AOX1 levels measured in HLC were found to be variable in the present
study. Cytosolic AOX1 levels in human livers were quantified using two different
acquisition methods in mass spectroscopy. Our lab had initially developed a DIA
method using SWATH-MS method to determine the relative protein levels of
various drug metabolizing enzymes which was published recently (Jamwal et al.,
2017). DDA was used for identification of proteins in the earlier method (details in
the method section). In due course, MaxQuant a quantitative proteomics
software was utilized which allows both in identifying and quantifying the proteins
of interest using the raw files generated from DDA (Cox et al., 2014). Both the
acquisition methods (DIA and DDA) demonstrated good correlation with each
other and reliability in using either method to quantify AOX1 protein. The
cytosolic FAS protein (a marker for progression of NAFLD) assessment gave
confidence in the reliability of the quantified protein levels using mass
spectroscopy. The leverage of total protein approach in MaxQuant is that it gives
accurate estimations of protein concentrations (Wisniewski et al., 2014). The
absolute values of pmol of AOX1/mg of total cytosolic protein values generated
from MaxQuant in the present study were comparable to other studies (Barr et
al., 2013; Fu et al., 2013). The variation in our study was observed to be about
25-fold (2 - 49 pmol/mg) in a novel bank of human livers. The AOX1 levels
quantified were much closer to the results reported by Barr et al. in pooled HLC
(Barr et al., 2013).
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The expression of drug metabolizing enzymes can be influenced by many
intrinsic and extrinsic factors (Rogers et al., 2002; Wilkinson, 2005; Fisher et al.,
2009; Merrell and Cherrington, 2011; Yang et al., 2013; He et al., 2015). Most
importantly factors like genetic polymorphism (Meyer, 2004), epigenetic
modifications like DNA methylation, histone protein modification or interaction
with microRNAs (Chuang and Jones, 2007; Ingelman-Sundberg and Gomez,
2010), and non genetic factors like age (Kinirons and O'Mahony, 2004), gender
(Beierle et al., 1999) or disease state (Elbekai et al., 2004) can influence the
expression of metabolizing enzymes. Pharmacokinetic variability in individuals
can be largely explained by the above mentioned factors influencing the
metabolizing enzymes and the knowledge of these factors is important to monitor
the drug response (Lin, 2007).
AOX1 is one of the highly abundant enzymes found in human liver
(Beedham, 1987; Nishimura and Naito, 2006). Non alcoholic fatty liver disease
(NAFLD) has demonstrated to influence the AOX1 levels. NAFLD is
characterized by a spectrum of conditions ranging from simple steatosis, nonalcoholic steatohepatitis with fibrosis progressing to cirrhosis (Targher et al.,
2008; Younossi et al., 2011). The rats fed with high-fat diet and primary
hepatocytes loaded with palmitic acid showed an increase in AOX1 expression
(Neumeier et al., 2006). It was observed that the primary hepatocytes for the
study were isolated and cultured from tissue samples obtained were not from
healthy subjects but from patients with liver tumors of colorectal cancer who were
undergoing hepatectomy. The levels of AOX1 could also be influenced by
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disease conditions like cancer. Certain phase I and II drug metabolizing
enzymes, AOX1, CYP1B1, GSTM3 and GSTP1 gene and protein expression
were found to be elevated in brain tumor specimens obtained from patients
(n=77) undergoing primary resection (Stavrinou et al., 2015). Whereas, in the
present study NAFLD did not have a significant impact on the AOX1 levels.
In an in vitro study (Fu et al., 2013) poor correlation was observed
between AOX1 activity and expression levels in HLC. Several demographic
factors along with protein mis-folding, polymorphism and co-factor deficiency
were suspected to be the reasons for observed poor correlation, but no clear
conclusions were drawn owing to their small sample size (n=20). In the same
study, chronic alcohol consumption in liver donors (n=2) decreased the AO
activity significantly but not the AOX1 levels. The AOX1 levels in the present
study were not altered significantly with increase in alcohol consumption. In other
in vitro studies, considerable inter-individual variability in the AO metabolism has
been observed using different substrates (Al-Salmy, 2001; Hutzler et al., 2014). It
would have been beneficial if the studies had AOX1 levels measured to correlate
with the observed activity and if any other demographic factors or posttransitional modifications are influencing the activity of the protein.
AO contains molybedenum and iron sulfur centers along with flavin
adenine dinucleotide (Beedham, 1985).

Iron deficiency diet decreased the

activity of AO in rats and increasing the iron reverted the activity to normal
indicating iron to have a significant impact on AO enzyme (Mackler et al., 1978).
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It is known that XO belongs to the same family as AO and is closely related
enzyme to AO (Beedham, 1985). In a rat study, XO levels and activity were
observed to be decreased with iron-depleted diet and increased when
supplemented with iron (Ghio et al., 2002). Both these studies indicate iron could
play an important role in modulating the AOX1 levels.
Many other unknown factors could be the reason for observed variability in
the AOX1 levels in our study. Recognizing the sources of variability could be
challenging as there may be other underlying unknown epigenetic factors,
disease state or dietary constituents influencing the enzyme. To the best of our
knowledge, for the first time, the effect of demographic factors on AOX1 levels in
a large number of human livers was studied.
Conflict of interest
Dr. Obach is an employee of Pfizer Pharmaceuticals. Other authors declare no
potential conflict of interest with any commercial entity whose products were
used in the study.

Acknowledgements
The financial support of Grant #UH3TR000963 from National Institutes of Health
is gratefully acknowledged.

98

References
Aebersold R, Burlingame AL, and Bradshaw RA (2013) Western blots versus
selected reaction monitoring assays: time to turn the tables? Mol Cell Proteomics
12:2381-2382.
Al-Salmy HS (2001) Individual variation in hepatic aldehyde oxidase activity.
IUBMB Life 51:249-253.
Barr JT, Jones JP, Joswig-Jones CA, and Rock DA (2013) Absolute
quantification of aldehyde oxidase protein in human liver using liquid
chromatography-tandem mass spectrometry. Mol Pharm 10:3842-3849.
Beedham C (1985) Molybdenum hydroxylases as drug-metabolizing enzymes.
Drug Metab Rev 16:119-156.
Beedham C (1987) Molybdenum hydroxylases: biological distribution and
substrate-inhibitor specificity. Prog Med Chem 24:85-127.
Beierle I, Meibohm B, and Derendorf H (1999) Gender differences in
pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37:529547.
Chuang JC and Jones PA (2007) Epigenetics and microRNAs. Pediatr Res
61:24R-29R.
Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, and Mann M (2014) Accurate
proteome-wide label-free quantification by delayed normalization and maximal
peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13:2513-2526.
Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss TS, Gabele E,
Kristiansen G, Hartmann A, and Hellerbrand C (2010) Expression of fatty acid
synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 3:505-514.
Elbekai RH, Korashy HM, and El-Kadi AO (2004) The effect of liver cirrhosis on
the regulation and expression of drug metabolizing enzymes. Curr Drug Metab
5:157-167.
Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson
SS, and Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in
humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab
Dispos 37:2087-2094.
Fu C, Di L, Han X, Soderstrom C, Snyder M, Troutman MD, Obach RS, and
Zhang H (2013) Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative
characterization of AOX1 expression level and activity relationship. Drug Metab
Dispos 41:1797-1804.
Garattini E, Mendel R, Romao MJ, Wright R, and Terao M (2003) Mammalian
molybdo-flavoenzymes, an expanding family of proteins: structure, genetics,
regulation, function and pathophysiology. Biochem J 372:15-32.
Ghio AJ, Kennedy TP, Stonehuerner J, Carter JD, Skinner KA, Parks DA, and
Hoidal JR (2002) Iron regulates xanthine oxidase activity in the lung. Am J
Physiol Lung Cell Mol Physiol 283:L563-572.
Han X, Aslanian A, and Yates JR, 3rd (2008) Mass spectrometry for proteomics.
Curr Opin Chem Biol 12:483-490.
He ZX, Chen XW, Zhou ZW, and Zhou SF (2015) Impact of physiological,
pathological and environmental factors on the expression and activity of human
99

cytochrome P450 2D6 and implications in precision medicine. Drug Metab Rev
47:470-519.
Hille R (2005) Molybdenum-containing hydroxylases. Arch Biochem Biophys
433:107-116.
Hopfgartner G, Tonoli D, and Varesio E (2012) High-resolution mass
spectrometry for integrated qualitative and quantitative analysis of
pharmaceuticals in biological matrices. Anal Bioanal Chem 402:2587-2596.
Hutzler JM, Yang YS, Brown C, Heyward S, and Moeller T (2014) Aldehyde
oxidase activity in donor-matched fresh and cryopreserved human hepatocytes
and assessment of variability in 75 donors. Drug Metab Dispos 42:1090-1097.
Ingelman-Sundberg M and Gomez A (2010) The past, present and future of
pharmacoepigenomics. Pharmacogenomics 11:625-627.
Jamwal R, Barlock BJ, Adusumalli S, Ogasawara K, Simons BL, and Akhlaghi F
(2017) Multiplex and Label-Free Relative Quantification Approach for Studying
Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes
Using SWATH-MS-MS. J Proteome Res.
Kinirons MT and O'Mahony MS (2004) Drug metabolism and ageing. Br J Clin
Pharmacol 57:540-544.
Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of
molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98.
Kurosaki M, Bolis M, Fratelli M, Barzago MM, Pattini L, Perretta G, Terao M, and
Garattini E (2013) Structure and evolution of vertebrate aldehyde oxidases: from
gene duplication to gene suppression. Cell Mol Life Sci 70:1807-1830.
Lepri S, Ceccarelli M, Milani N, Tortorella S, Cucco A, Valeri A, Goracci L, Brink
A, and Cruciani G (2017) Structure-metabolism relationships in human-AOX:
Chemical insights from a large database of aza-aromatic and amide compounds.
Proc Natl Acad Sci U S A 114:E3178-E3187.
Lin JH (2007) Pharmacokinetic and pharmacodynamic variability: a daunting
challenge in drug therapy. Curr Drug Metab 8:109-136.
Mackler B, Person R, Miller LR, Inamdar AR, and Finch CA (1978) Iron
deficiency in the rat: biochemical studies of brain metabolism. Pediatr Res
12:217-220.
Merrell MD and Cherrington NJ (2011) Drug metabolism alterations in
nonalcoholic fatty liver disease. Drug Metab Rev 43:317-334.
Meyer UA (2004) Pharmacogenetics - five decades of therapeutic lessons from
genetic diversity. Nat Rev Genet 5:669-676.
Nakamura K, Hirayama-Kurogi M, Ito S, Kuno T, Yoneyama T, Obuchi W,
Terasaki T, and Ohtsuki S (2016) Large-scale multiplex absolute protein
quantification of drug-metabolizing enzymes and transporters in human intestine,
liver, and kidney microsomes by SWATH-MS-MS: Comparison with MRM/SRM
and HR-MRM/PRM. Proteomics 16:2106-2117.
Neumeier M, Weigert J, Schaffler A, Weiss TS, Schmidl C, Buttner R, Bollheimer
C, Aslanidis C, Scholmerich J, and Buechler C (2006) Aldehyde oxidase 1 is
highly abundant in hepatic steatosis and is downregulated by adiponectin and
fenofibric acid in hepatocytes in vitro. Biochem Biophys Res Commun 350:731735.
100

Nishimura M and Naito S (2006) Tissue-specific mRNA expression profiles of
human phase I metabolizing enzymes except for cytochrome P450 and phase II
metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
Paragas EM, Humphreys SC, Min J, Joswig-Jones CA, and Jones JP (2017) The
two faces of aldehyde oxidase: Oxidative and reductive transformations of 5nitroquinoline. Biochem Pharmacol.
Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde
oxidase: an enzyme of emerging importance in drug discovery. J Med Chem
53:8441-8460.
Rashidi MR and Soltani S (2017) An overview of aldehyde oxidase: an enzyme
of emerging importance in novel drug discovery. Expert Opin Drug Discov
12:305-316.
Rogers JF, Nafziger AN, and Bertino JS, Jr. (2002) Pharmacogenetics affects
dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med
113:746-750.
Stavrinou P, Mavrogiorgou MC, Polyzoidis K, Kreft-Kerekes V, Timmer M,
Marselos M, and Pappas P (2015) Expression Profile of Genes Related to Drug
Metabolism in Human Brain Tumors. PLoS One 10:e0143285.
Targher G, Marra F, and Marchesini G (2008) Increased risk of cardiovascular
disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
Diabetologia 51:1947-1953.
Wilkinson GR (2005) Drug metabolism and variability among patients in drug
response. N Engl J Med 352:2211-2221.
Wisniewski JR, Hein MY, Cox J, and Mann M (2014) A "proteomic ruler" for
protein copy number and concentration estimation without spike-in standards.
Mol Cell Proteomics 13:3497-3506.
Wisniewski JR and Rakus D (2014) Multi-enzyme digestion FASP and the 'Total
Protein Approach'-based absolute quantification of the Escherichia coli proteome.
J Proteomics 109:322-331.
Yang L, Price ET, Chang CW, Li Y, Huang Y, Guo LW, Guo Y, Kaput J, Shi L,
and Ning B (2013) Gene expression variability in human hepatic drug
metabolizing enzymes and transporters. PLoS One 8:e60368.
Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, and Srishord
M (2011) Changes in the prevalence of the most common causes of chronic liver
diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol
9:524-530 e521; quiz e560.

101

Tables
Table. III-1. Detailed donor demographics

N (total)

104

Male, Female

49, 55

Ethnicity# (n) C, AA, H

89, 10, 5

Age1 (years)

50.2 ± 1.1

Body-mass index1 (kg/m2)

31.4 ± 1.07

Diabetes mellitus (no, yes)

51, 53

Liver weight1 (kg)

1.59 ± 0.58

Body weight1 (kg)

88.7 ± 2.84

Smoking (no, yes)

46, 58

Drug Usage (no, yes)

83, 21

Alcohol consumption

42, 21, 19,

(Scale 0 -4) (no –heavy)

10, 12

NAFLD (Scale 0 - 2)
(none - disease progression)
#C-Caucasian,

41, 34, 29

AA-African-American, H-Hispanic; 1mean±SE.
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Table. III-2. Effect of demographic factors on AOX1 levels

Factors

Groups

AOX1
(pmol/mg)1

Male (n=55)

26.7 ± 1.2

Female (n=49)

26.9 ± 1.1

AA (n=10)

31 ± 0.9

CC (n=89)

26.4 ± 3

H (n=5)

25.2 ± 1

0 (n=42)

27 ± 1.1

Alcohol

1 (n=21)

28.8 ± 2

Consumption

2 (n=19)

28.2 ± 2.4

Scale

3 (n=10)

24.6 ± 1.8

4 (n=12)

22.4 ± 2.5

Yes (n=58)

26.7 ± 1.1

NO (n=46)

26.6 ± 1.3

Yes (n=53)

26.1 ± 1

NO (n=51)

27.7 ± 1.3

Gender

Ethnicity#

Smoking

Diabetes

NAFLD (Scale 0 (n=41)
0-2) (none 1 (n=34)
progression
2 (n=29)
of disease)
#C-Caucasian,

Test

P value

Mann-Whitney U

0.94

Kruskal Wallis

0.459

Kruskal Wallis

0.466

Mann-Whitney U

0.587

Mann-Whitney U

0.797

Kruskal Wallis

0.254

27.7 ± 1.3
25.9 ± 1.2
26.5 ± 1.9

AA-African-American, H-Hispanic; 1mean±SE
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Legend of Figures
Fig. 1. Correlation plots
Fig. 2. Correlation plot between DIA (SWATH-MS-MS) and DDA for AOX1 levels
Fig. 3. Distribution of AOX1 levels across individual human liver cytosolic
samples (n=104)
Fig. 4. Cytosolic fatty acid synthase in NAFLD.
Fig. 5. Effect of ethnicity on AOX1 levels
Fig. 6. Effect of alcohol on AOX1 levels
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Fig. III-1. Correlation plots (a) correlation between surrogate peptides of AOX1
and (b) correlation between one of the unique peptide and sum of the peptides
for AOX1 from SWATH-MS was considered significant (p<0.05) using correlation
coefficient Spearman r.
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Fig. III- 2. Correlation plot between DIA (SWATH-MS) and DDA for AOX1 levels.
Correlation between two acquisition methods SWATH-MS and traditional DDA
was considered significant (p<0.05) using correlation coefficient Spearman r
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Fig. III-3. Distribution of AOX1 levels across individual human liver cytosolic
samples (n=104). The AOX1 levels ranged from of 2-49 pmol/mg cytosolic
protein (19.5 fold).

107

Fig. III-4. Cytosolic fatty acid synthase in non alcoholic fatty liver disease
(NAFLD). Increase in cytosolic fatty acid synthase with progress in NAFLD was
observed to be significant in HLC. NAFLD score (0 - 2) indicates none – 0, non
alcoholic fatty liver – 1, progression to non-alcoholic steatohepatitis – 2. Column
and error bars represent mean±SE. *P<0.05 reported from nonparametric
Kruskal-Wallis test (2-sided).
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Fig. III-5. Effect of ethnicity on AOX1 levels. Effect of ethnicity (AA – African
American, CC – Caucasian, H – Hispanic) on AOX1 was observed to be not
significant across the groups in HLC Column and error bars represent mean±SE.
P >0.4 reported from nonparametric Kruskal-Wallis test (2-sided).
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Fig. III-6. Effect of alcohol on AOX1 levels. Alcohol consumption had no
significant effect on AOX1 levels in HLC. Alcohol consumption scale (0-4)
indicated none to heavy drinking. (None = 0, Safe = 1, Moderate = 2, Heavy = 3).
Column and error bars represent mean±SE. P >0.4 reported from nonparametric
Kruskal-Wallis test (2-sided).
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Clinical Pharmacokinetics of a Major Hydroxy Metabolite of PF-5190457, a
Ghrelin Receptor Inverse Agonist- Evidence from In vivo and In vitro
Studies
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT


PF-5190457 is a ghrelin receptor inverse agonist. It has been proposed to
treat alcohol use disorder and type 2 diabetes. In phase 1 clinical studies,
PF-5190457 was well tolerated in healthy volunteers and subjects in alcohol
use disorder.



PF-5190457 is majorly metabolized by aldehyde oxidase enzyme to (add the
name of AO metabolite)



Aldehyde oxidase is a cytosolic enzyme that displays high interindividual
variability with different substrates

WHAT THIS PAPER ADDS
The manuscript, for the first time, reports the pharmacokinetics of PF-5190457
and its major hydroxy metabolite in alcoholic subjects. The half-life of the
metabolite was higher in comparison to the parent drug. The metabolism of PF5190457 was found to be variable across various human liver cytosolic fractions
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AIM: To investigate the pharmacokinetics of PF-5190457 and its major hydroxy
metabolite at 50 and 100 mg doses in alcoholic patients. Moreover, an in vitro
study was conducted to examine the variability of PF-5190457 metabolite
formation in individual human liver cytosol (HLC).
METHODS: The concentrations of PF-5190457 and its metabolite in patient
plasma samples obtained through phase 1 b clinical trials were determined using
a validated LC-MS/MS method. Previous studies from our group has
demonstrated that PF-5190457 is metabolized by aldehyde oxidase (AOX1) to a
major hydroxyl metabolite. To determine the variability of hydroxy metabolite
formation, the substrate was incubated in n=10 individual HLCs. The AOX1
protein levels were obtained by mass spectroscopy using a label free quantitation
approach and information dependent acquisition.
RESULTS: The half-life of parent and metabolite was found to be approximately
6 and 13 h respectively for both doses. The CL int in HLC for PF-5190457 ranged
from 0.4 – 7.1 µL/min/mg protein with 17-fold variability. The estimated AOX1
protein expression were much closer ranging from 16.8 - 44.1 pmol/mg (2.6-fold
variability). The correlation between AOX1 protein expression and aldehyde
oxidase (AO) activity was poor.
CONCLUSION: The pharmacokinetics of PF-5190457 and its major metabolite
was evaluated after oral administration of 50 and 100 mg and importantly the
half-life of the metabolite was found to be longer than the parent. Inter-individual
variability in the hydroxy metabolite formation was observed in HLC indicating a
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need to assess the influence of various demographic factors on a larger number
of samples.
Keywords
Aldehyde oxidase, alcoholism, IDA Information dependent acquisition, HLC
Human liver cytosol, PF-5190457, XO Xanthine Oxidase
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Introduction
PF-5190457 is a ghrelin receptor inverse agonist and is currently undergoing
clinical trials to treat alcoholism and type 2 diabetes mellitus [1-3]. This drug was
originally developed by Pfizer and the tolerability of the compound in healthy
volunteers was evaluated. The pharmacokinetics of the drug in healthy
volunteers (n=35) was determined at single (2, 10, 40, 50, 100, 150, and 300 mg)
and multiple (2, 10, 40 and 100 mg BID for two weeks). The absorption of the
PF-5190457 was observed to be rapid and the elimination half-life was found to
be ~9 h [4].
We have previously showed that PF-5190457 is metabolized to a hydroxy
metabolite by the molybdenum co-factor containing enzymes AO and xanthine
oxidase (XO). The contribution of AO in the metabolism of the drug was identified
to more dominant (manuscript II). AO enzyme is gaining increasing importance in
the metabolism and clearance of new drug entities in the recent years [5, 6].
There are various in vitro studies in S9 fraction, cytosol and hepatocytes
demonstrating high interindividual variability in AO activity with use of various
substrates [7-9].

For example, AO activity measured in cytosol from same

donors using carbazeran, zoniporide and phthalazine as probe substrates varied
90, 42 and 17-fold respectively [10].
In the present paper, we determine the concentration of PF-5190457 and its
hydroxy metabolite in alcoholic patients (N=12) enrolled in a phase 1b clinical
study in subjects with alcohol use disorder. In an effort to address the variability
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of PF-5190457 metabolism with respect to AO activity, the metabolite formation
was measured in HLC from 10 individual donors. In addition, the measured
activity was correlated with the expression of AO protein and the characteristics
of HLC donors were examined to understand the impact of demographic
variables such as age, gender, ethnicity, smoking, alcohol, medical history.

Materials and methods
Chemicals and reagents
PF-5190457 (Mw 512.67) and tacrine (Mw 198.26) were obtained from SigmaAldrich (St. Louis, MO, USA). PF-6870961 (Hydroxy metabolite Mw 528.23) was
synthesized as described in manuscript II. LC-MS grade methanol and formic
acid were obtained from Fisher Scientific (FairLawn, NJ, USA). Blank K2EDTA
human plasma from six subjects (three male, three female) were obtained from
Bioreclamation (IVT Inc., Westbury, NY, USA).
Pharmacokinetic study in Alcohol Dependent Subjects
Phase 1b clinical study of PF-5190457 was conducted in non treatment seeking
alcohol dependent individuals at NIH clinical center at Bethesda. Men and
women between 21 – 65 years were eligible. The study was approved by the
University of Rhode Island Institutional Review Board HU# 123.172. The
participants of the study have filled out the informed consent form prior to the
study. Briefly, the key inclusion criteria were heavy drinking (on an average for
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men – 21 drinks and women – 14 drinks a week) and good health which was
confirmed by medical history, physical examination, ECG, blood/urine lab tests.
Moreover, the female subjects must be of non-childbearing potential, and male
subjects must follow contraception for a period of 28 days after dosing. Briefly the
key exclusion criteria were interest in receiving treatment for alcohol use
disorder, diagnosis of substance dependence (other than alcohol and/or
nicotine), schizophrenia, bipolar disorder, or other psychoses, clinically significant
medical abnormalities, heart rate >100 at screening on two separate
measurements given potential of study medication to increase heart rate and BMI
less than or equal to 18.5.
This phase 1b study was a within-subject design and a single blind doseescalating placebo controlled inpatient study. Subjects (N=12) were admited to
the clinical research center (NIH clinical center at Bethesda) for three visits
(placebo, a dose of 50 mg and a dose of 100 mg). The subjects received PF5190457 orally as solution every twelve hours for a total of 5 doses. Blood
samples for pharmacokinetics analysis were collected in the morning of the third
day of hospital stay after the administration of a fifth dose of PF-5190457 at
various time points (0, 15, 30, 45, 60, 90, 120, 150,180, 210, 240, 360, 480, 1350
and 1440 min). The concentration of PF-5190457 and its hydroxy metabolite (PF6870961) in plasma were measured using an LC-MS/MS assay specifically
developed and validated for the purpose of this study as described in manuscript
I. Briefly, the plasma extraction method involved simple precipitation in methanol
and samples were analyzed using an Acquity UPLC system coupled with Xevo
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TQ MS detector (Waters Corp, Milford, MA, USA). The pharmacokinetic
parameters were determined using non-compartmental analysis. Cmax (maximum
observed drug concentration during the study), AUC0–24 is area under the plasma
concentration–time curve measured for 24 h, using the trapezoidal rule, AUClast-∞
is based on the last observed concentration extrapolated to infinity time
(Cplast/k), k is rate constant, AUC0–∞ is area under the curve from time 0
extrapolated to infinite time (AUC0–24 + AUClast-∞), Tmax is time to observe
maximum drug concentration, and T1/2 is half-life determined by 0.693/K). The
apparent volume of distribution and clearance were calculated using the relations
Vz/F= Dose / (AUC0–∞* k) and Cl/F = Dose / AUC0–∞ respectively [11]. The
pharmacokinetic parameters were evaluated for each subject at respective doses
(50 and 100 mg).

Human Liver Selection for In vitro studies
The livers (n=10) for the in vitro study were selected from the existing novel
human liver bank (n=104) in the lab purchased from Sekisui XenoTech LLC
(Kansas City, KS). The primary criteria for selecting the livers in this study were
based on ethnicity (African American - AA, Caucasian - CC). It is a common
practice to perfuse livers with University of Wisconsin solution containing
allopurinol (a well-known XO inhibitor) and its primary metabolite oxypurinol and
they have shown to completely inhibit XO activity [12]. From our liver bank, we
identified that only n=9 out of 104 were allopurinol free and none of the donors
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were African American. For the purpose of uniformity, the livers selected for the
present study were containing allopurinol/oxypurinol which was detected by mass
spectrometry analysis as described in Manuscript II. The livers were well
characterized and documented for demographic factors like age, gender, BMI,
weight of body and liver, ethnicity, alcohol consumption, smoking, along with
medical history for diabetes and non-alcoholic fatty liver disease. Table 1 shows
demographic characteristics of donors.
Human liver cytosol Incubations
The procedure that was used to prepare liver cytosol has been described
elsewhere [13]. The hydroxy metabolite formation was examined in the 10
individual HLC selected over the PF-5190547 concentration range of 0 - 400 µM
and cytosolic protein concentration of 0.1 mg/ml. All experiments were performed
in triplicates. The details for incubation conditions and subsequent LC-MS/MS
analysis of cytosolic samples in Acquity UPLC coupled to Xevo TQ MS detector
(Waters Corp, Milford, MA, USA) for determining the kinetic parameters are
described in Manuscript II. The velocity of the reaction was calculated from
Michealis Menton equation and CLint (intrinsic clearance) was calculated as
Vmax/Km where Vmax is maximum rate of product formation and Km is MichaelisMenten constant (substrate concentration required for an enzyme to reach onehalf of its maximum velocity).
Estimation of AOX1 protein expression in Human liver cytosol using LCMS/MS
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AOX1 levels (pmol/mg) in cytosolic fractions were determined using a label free
approach on mass spectrometry as described in Manuscript III. Briefly, the
digestion of proteins in cytosolic samples was performed using trypsin and the
resulting peptides were analyzed using information dependent acquisition (IDA)
mode on an AB Sciex TripleTOF 5600+ mass spectrometer. The subsequent
data analysis was performed using MaxQuant (Version 1.5) proteomics software
for protein (AOX1) identification by searching against UniProt human protein
database (updated Oct 2016) and quantification. The maximum false peptide
discovery rate was specified as 0.01. AOX1 protein was calculated based on the
raw spectral protein intensity from label-free quantification (LFQ) intensities of the
MaxQuant software output using the “Total Protein Approach” (TPA).
Statistical analysis
Statistical analysis was performed with SPSS version 24 (IBM Analytics, Armonk,
NY), and Prism® version 6 (GraphPad Software Inc., San Diego, CA) was used
for graphing and calculation of kinetic parameters (Vmax and Km). Since most of
the datasets were not normally distributed, nonparametric methods were
generally used for statistical analyses. Non-parametric Mann-Whitney U test (2tailed) was used to compare the effect of ethnicity and other demographic factors
on enzyme activity and AOX1 levels. The correlation was studied using
nonparametric Spearman correlation analysis.
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Results
Pharmacokinetics analysis
The validated LC-MS/MS method (Manuscript I) has been successfully applied to
measure the concentrations of PF-5190547 and its hydroxy metabolite after oral
administration of the drug at 50 mg and 100 mg in human plasma. The mean
concentration versus time profiles of the analytes in human plasma are shown in
Figure 1 a and b. The plasma concentration ranges of the analytes were
measurable within their calibration curves. The concentrations of PF-5190547
and its hydroxy metabolite ranged from 2.8 to 213.3 ng/mL and 3.9 to 73.8 ng/mL
for 50 mg dose and 3.5 to 813.7 ng/mL, and 6.6 to 124.8 ng/mL for 100 mg dose,
respectively. Pharmacokinetic details for the area under the curve from initial
time to infinity (AUC0–∞), Cmax, Tmax, Vz/F, Cl/F and t1/2 are shown in Table 2 for
both 50 and 100 mg doses. The half-life for the metabolite (14.7 ± 2.1 and 12.8 ±
2.2 h) at both the doses (50 and 100 mg) was observed to be longer in
comparison to the parent (6.2 ± 1 and 5.8 ± 0.5 h).
Individual PF-5190457 metabolism in HLC
Formation of hydroxy metabolite of PF-5190457 in this study was mediated by
AO as HLCs in the selected livers were devoid of XO activity. In general,
individual variation in AO activity (Figure 2) was observed in all kinetic
parameters for the hydroxy metabolite formation (Table 3). Km and Vmax values
ranged from 8.1 to 68.3 µM and 0.02 to 0.41 nmol/min/mg protein respectively.
CLint was found to be between 0.4 – 7.1 µL/min/mg (~ 17 fold variability). African
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American donors exhibited marginally lower AO activity in comparison to
Caucasian donors. However, no significant association (P>0.1,) was observed
between ethnicity and AO activity (Figure 3a). The effect of other demographic
factors

was

examined

and

no

significant

relationship

was

observed.

Nevertheless, the effect of smoking on AO activity was observed to be significant
with p<0.017 (Figure 4a). The limitation of this study was small sample size as
there were only n=3 out of 10 livers were obtained from non-smoker individuals.
Expression of AOX1 protein in HLC and correlation to In vitro AO activity
The AOX1 levels obtained from data analysis using MaxQuant TPA approach
ranged from 16.8 – 44.2 pmol/mg with 2.6 fold difference (Figure 5) across the
examined HLCs. There was no significant effect of ethnicity (Figure 3b) and
smoking (Figure 4b) on AOX1 levels observed. Moreover, other demographic
factors mentioned in Table 1 did not significantly influence AOX1 levels. The AO
activity characterized by rate of formation of hydroxy metabolite showed a weak
correlation (Figure 6) (Spearman r = 0.2 and p>0.5) with AOX1 protein levels.

Discussion
The in vivo study evaluated pharmacokinetics of PF-5190457 and its hydroxy
metabolite in alcohol dependent subjects. The pharmacodynamics of the drug in
the same study population is evaluated by our lab and will be discussed
elsewhere.

Previously,

published

study

determined

PF-5190457

pharmacokinetics in healthy subjects [4] and the half-life of the parent was
123

observed to be higher in comparison to our study in alcoholic subjects (~9 vs ~6
hours) whereas, the other parameters (Cmax, Tmax) were comparable. It could be
because of differences in blood sampling points or differences in the population
(healthy vs alcoholic subjects).
The kinetics of major hydroxyl metabolite was not reported previously. The
findings from the present study also indicate that the half-life of the hydroxy
metabolite in heavy drinkers was higher in comparison to the parent drug. The
higher exposure of the metabolite in the body could be of an advantage if the
metabolite would have any pharmacological significance and further evaluations
with respect to safety profile and byproducts of the hydroxy metabolite are
necessary. The clinical study for PF-5190457 recruited n=12 subjects and the
majority of the subjects where African American (n=11). The differences in
ethnicity could affect the pharmacokinetics and subsequent pharmacodynamics
of the drug [14, 15]. In addition, the variability of pharmacokinetic parameters is
largely explained by genetic variation in metabolizing enzymes [16], disease
state, physiological and environmental factors [17, 18]. The primary objective for
the in vitro study in the present paper was to determine differences in metabolism
of PF-5190457 with respect to ethnicity (African American vs. Caucasians) and
inter-individual variability.
PF-5190457 is predominantly metabolized by AO enzyme (Manuscript II). Wide
variability has been reported for substrates metabolized by AO and the
metabolism has demonstrated to be highly substrate dependent with high donor
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to donor variability [10, 19, 20]. An example, the AO activity was measured using
different probe substrates N-[(2-dimethylamino) ethyl] acridine-4-carboxamide
(DACA) and benzaldehyde in the same HLC donors (n=13). The CLint with
respect to DACA and benzaldehyde was 18-fold and 5-fold respectively across
the individual donors [21]. In our study, the CLint varied 17-fold for PF-5190457
across individual HLC. Further, weak correlation between the AOX1 protein
levels and AO activity was observed which were in accordance with findings from
another in vitro study in HLC [10]. Few studies published to determine correlation
between AO protein and activity. The hydroxy metabolite formation was found to
be reduced in AA but the non-significant change could be because of the small
sample size of HLC. There is only one study so far, showing the influence of
ethnicity on AO activity in cryopreserved hepatocytes using O6-benzylguanine as
a probe substrate which showed no significant effect between AA (n=7) vs CC
(n=50) on AO activity. The above-mentioned study too had several livers from AA
donors.

Further exploration of other demographic factors on PF-5190457

metabolism indicated smoking could lead to low AO activity but study in large
sample size of donors would be essential for confident results. There is only
limited information published on the impact of smoking on AO protein and
activity. One study discussed no relationship between AO activity and smoking
but it was based on 1 out of 13 HLC donors with tobacco use [21]. In one other
study AO activity in large sample size (75 donors) was assessed using
hepatocytes and the livers were characterized for tobacco use but the effect of
smoking was not mentioned [22]. It is also known that nicotine is primarily
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metabolized by CYP1A2 to an iminium ion and then the second step of
metabolism primarily involves AO enzyme [23-25]. Fu et al. showed chronic
alcohol use in (n=2) HLC donors could influence the AO activity but the small
sample size was a limitation. The effect of both smoking and alcohol use could
have a significant impact on AO activity and warrants further examination in a
larger number of samples.
AO protein is a homodimer and disruption in homodimer formation can affect AO
activity [26]. Other reasons for variation in AO activity could be protein misfolding
or genetic polymorphism [27]. Genetic polymorphism of hAOX1 was studied in
Italian population and the presence of functionally inactive hAOX1 allelic variants
enzymes was determined [26]. To the best of our knowledge there are no studies
conducted exclusively in AA population to assess the presence of allelic variants.
One study determined the impact of common single nucleotide polymorphism on
the AO activity in 75 donors in which there were only seven African American
and 50 Caucasians and the rest were Hispanic. The study showed no statistical
significance for polymorphism on AO activity [22].
Dietary constituents could also influence the AO activity [28]. AO enzyme
contains iron along with molybdopterin cofactor and flavin adenine dinucleotide. It
has been reported that iron deficiency could lead to lower AO activity as reported
in a rat study. AO is the main enzyme for serotonin degradation and rats on iron
deficient diet exhibited significantly increased concentrations of serotonin. The
levels of serotonin reverted back to normal when the rats were supplemented
with iron [29]. It is known that AO and XO enzyme share closely related
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structures. The XO expression and activity in lung were reduced in rats fed on an
iron-depleted diet and increased in rats supplemented with iron [30]. AO belongs
to the same family iron supplementation could be one of the reasons for the
variability observed in AO activity.
The findings from the present study could be important as variability in PF5190457 was observed across individual HLC. Since multiple factors could be
contributing to variability in AO activity, larger sample size is necessary to
address the connections.
In conclusion, the manuscript describes the successful application of LC-MS/MS
method to a pharmacokinetic study of PF-5190547 at 50 and 100 mg in healthy
volunteers in phase 1b clinical trials to treat alcoholism. The in vitro study shows
donor variability in hydroxylation of PF-5190457 in human liver cytosol.
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FIGURE LEGENDS
Figure 1 (a) and (b) Plasma concentration time profiles for parent (PF5190547) and hydroxy metabolite after the administration of 50 and 100 mg
dose respectively. Data are shown as mean ± SD at each time point.
Figure 2 Bar chart demonstrating AO activity in individual human liver
cytosol. AO activity was characterized by hydroxylation of PF-5190457 across
n=10 human liver cytosol. The data was found to be non normally distributed with
a 20 fold variability.
Figure 3 (a) Effect of ethnicity on AO activity and (b) AOX1 levels. AO
activity in African American, AA (n=5) was observed to be lower in comparison to
Caucasians, CC (n=5) but not significantly different (p>0.1). AOX1 proteins levels
were observed to be not significantly different across both the groups
Figure 4 (a) Effect of smoking on AO activity and (b) AOX1 levels. AO
activity in smokers (n=7) was observed to be significantly lower (p<0.017 Mann
Whitney U test). in comparison to and non-smokers (n=3), CC (n=5). AOX1
proteins levels were observed to be not significantly different across both the
groups.
Figure 5 Distribution of AOX1 protein levels in 10 individual human liver
cytosol. The range of AOX1 levels was between 16 – 44 pmol/mg as determined
by label free quantification approach using information dependent acquisition on
mass spectroscopy.
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Figure 6. Correlation between AO activity and AOX1 levels (pmol/mg). Open
circles represent Caucasians and closed circles for African Americans. The
equation of the line for the best fit was generated by least square linear
regression analysis. Statistical significance of the correlations was determined by
the Spearman correlation test. A weak correlation (p>0.5) was observed between
AO activity (hydroxy metabolite of PF-5190457) formation and AOX1 levels was
observed.
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Table IV-1. Demographics and baseline characteristics of the human
subjects
Number (N)

12

Females (n, %)

1 (8%)

Age (years)
Range

23-58

M ± SD

40.5 ± 13.1

Median

40.0

Race/Ethnicity (%)
African-Americans

11 (91.7%)

Caucasians

1 (8.3%)

Cigarette smoking Status (n, %)
Smoker

9 (75.0%)

Non-Smoker

3 (25.0%)

DSM-IV diagnosis of alcohol dependence (n, %)

11 (91.7%)

BMI, Kg/m2, (M ± SD)

27.1 ± 4.7

90-day baseline average drinks/drinking day, (M ± SD)

10.7 ± 4.2
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Table IV-2. Demographic and donor data details

ID

Gender Age Ethnicity Smoking Drug_Use

Medical
History

HLC_01 M

44

AA

Yes

Yes

Diabetes

HLC_02 F

49

AA

Yes

No

Diabetes

HLC_03 M

48

AA

Yes

Yes

No

HLC_04 M

23

AA

Yes

Yes

No

HLC_05 F

49

AA

Yes

No

Diabetes

HLC_06 F

78

CC

No

No

Diabetes

HLC_07 F

53

CC

No

No

Diabetes

HLC_08 M

59

CC

Yes

No

No

HLC_09 M

44

CC

No

Yes

No

HLC_10 M

53

CC

Yes

No

Diabetes
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Table IV-3. Summary of pharmacokinetic parameters
a. 50 mg PF-5190457 dose (mean ± SD, n = 12)
Dose-50 mg

Parent (PF-5190457)

Hydroxy Metabolite

AUC (0-∞) (ng.min)/mL

53184.8 ± 20694.8

33945.5 ± 9753.4

Cmax (ng/mL)

134.3 ± 43.8

39.8 ± 14.1

Tmax (min)

56.2 ± 24

56.2 ± 12.9

Half life (h)

6.2 ± 1

14.7 ± 2.1

CL/F (L/h)

60.7 ± 16.8

93.6 ± 28.8

Vz/F(L)

554.7 ± 156.7

2069.4 ± 781.2

b. 100 mg PF-5190457 dose (mean ± SD, n = 12)

Dose-100 mg

Parent (PF5190457)

Hydroxy Metabolite

AUC (0-∞) (ng.min)/mL

108528.7 ± 64556.3

57497.6 ± 18588.6

Cmax (ng/mL)

305.6 ± 189.4

76.2 ± 23.1

Tmax (min)

50 ± 28.8

68.7 ± 48

Half life (h)

5.8 ± 0.5

12.8 ± 2.2

CL/F (L/h)

70 ± 40.2

111.6 ± 33.9

Vz/F(L)

604.7 ± 364.5

2162.7 ± 930.9

AUC = area under the plasma concentration time curve, C max = maximum
observed plasma concentration, Tmax = time of Cmax, Cl/F = Apparent
Clearance, Vz/F = Apparent volume of distribution
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Table IV-4. Kinetic parameters for hydroxy metabolite formation of PF-5190457
in individual human liver Cytosol
Vmax

Km

CLint

AOX1

ID

(nmol/min/mg)

(µM)

(µL/min/mg)

(pmol/mg)

HLC_01

0.06

17.7

3.4

25.70

HLC_02

0.13

27.9

4.6

43.40

HLC_03

0.14

57.1

2.5

23.21

HLC_04

0.07

43.7

1.7

20.54

HLC_05

0.04

8.1

5.3

44.29

HLC_06

0.23

42.5

5.4

25.37

HLC_07

0.24

36.1

5.4

32.06

HLC_08

0.02

68.3

0.4

16.83

HLC_09

0.41

58.1

7.1

30.37

HLC_10

0.15

43.4

2.0

22.47
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Figure IV-1 (a) and (b).
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